Original Article
Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events
N Engl J Med 2001; 344:1959-1965June 28, 2001
- Abstract
Background
Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia.
Methods
The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events.
Results
The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.87).
Conclusions
Statin therapy may be effective in the primary prevention of coronary events among persons with relatively low lipid levels but with elevated levels of C-reactive protein.
Media in This Article
Figure 1
Relative Risks (and 95 Percent Confidence Intervals) Associated with Lovastatin Therapy, According to Base-Line Lipid and C-Reactive Protein Levels.Table 1
Median C-Reactive Protein Levels at Base Line and after One Year of Therapy in the Lovastatin and Placebo Groups.Article Activity
- Article
Both the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) and the West of Scotland Coronary Prevention Study demonstrated that inhibitors of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase (statins) reduce the risk of first coronary events.1,2 However, the use of statins for primary prevention has not been widely adopted, in part because the number of persons who need to be treated to prevent one clinical event is relatively large and the cost of this approach is substantial.3
A method of distinguishing high-risk from low-risk patients might make possible better targeting of statin therapy for primary prevention.4 For example, restricting statin use to those with overt hyperlipidemia improves the cost effectiveness of the therapy,5 and the current guidelines of the National Cholesterol Education Program recommend that statins be prescribed for primary prevention when low-density lipoprotein (LDL) cholesterol levels exceed 160 mg per deciliter (4.14 mmol per liter).6 Unfortunately, half of all coronary events occur in persons without overt hyperlipidemia.7 Thus, lipid screening alone may fail to identify all high-risk subgroups that are likely to benefit from statin therapy.
Several studies suggest that measurement of the inflammatory marker C-reactive protein may provide a useful method of assessing the risk of cardiovascular disease in apparently healthy persons, particularly when lipid levels are low.8-12 Furthermore, statin therapy has been shown to reduce C-reactive protein levels independently of its effect on cholesterol,13,14 and statins may have antiinflammatory properties.15 Although the addition of an evaluation of C-reactive protein levels to standard lipid screening has been shown to improve risk prediction in the primary prevention of acute coronary events,9,16 there are no data demonstrating that C-reactive protein screening can identify subgroups of patients who are more or less likely to benefit from statin therapy.
To address this issue, we measured the level of C-reactive protein both at base line and after one year of follow-up among 5742 of the 6605 participants enrolled in a randomized, double-blind, placebo-controlled trial of lovastatin in the primary prevention of acute coronary events in persons with average levels of total cholesterol and below-average levels of high-density lipoprotein (HDL) cholesterol.1
Methods
AFCAPS/TexCAPS was a primary-prevention trial of lovastatin, conducted between 1990 and 1998, that included 6605 men and women at two sites in Texas, the Lackland Air Force Base and the University of North Texas Health Science Center.1,17 Men 45 to 73 years old and postmenopausal women 55 to 73 years old who had average levels of total and LDL cholesterol and below-average levels of HDL cholesterol were eligible. Persons with uncontrolled hypertension, secondary hyperlipidemia, diabetes requiring insulin, or a body mass 50 percent greater than desirable were excluded.
Participants who provided written informed consent, met all the entrance criteria, and completed a 12-week run-in period during which they followed the American Heart Association Step I diet were randomly assigned to receive either lovastatin (20 mg per day) or matching placebo. The dose of lovastatin was increased in a double-blind manner to 40 mg of lovastatin per day if the LDL cholesterol level was higher than 110 mg per deciliter (2.84 mmol per liter) at the three-month visit. We conducted follow-up for an average of 5.2 years to monitor the occurrence of first acute coronary events, which were prospectively defined as fatal or nonfatal myocardial infarction, unstable angina, or sudden death from cardiac causes. As we previously reported,1 assignment to the lovastatin group was associated with a rate of reaching this primary clinical end point that was 37 percent lower than that in the placebo group (relative risk, 0.63; 95 percent confidence interval, 0.50 to 0.79; P<0.001).
Laboratory Analyses
A highly sensitive latex-based immunoassay (Dade Behring, Newark, Del.) was used to determine the levels of C-reactive protein in blood obtained at the time of randomization and at one year.18 Lipid levels were measured in a laboratory accredited by the Lipid Standardization Program of the Centers for Disease Control and Prevention. In total, 5742 of the 6605 participants (87 percent) had blood available for analysis and underwent successful evaluation for high-sensitivity C-reactive protein and lipid levels. The median LDL cholesterol level (149.1 mg per deciliter [3.86 mmol per liter]) and the median ratio of total to HDL cholesterol (5.96) among these 5742 participants were virtually identical to the median level and ratio (149.3 mg per deciliter [3.86 mmol per liter] and 5.98, respectively) in the study cohort as a whole.
Statistical Analysis
After the study cohort had been divided into quartiles on the basis of C-reactive protein levels, Cox regression analysis was used to test for an association between base-line levels of C-reactive protein and the risk of acute coronary events. Adjusted risk estimates were obtained from analyses that also controlled for age, sex, smoking status, hypertension, parental history with respect to coronary disease, and lipid levels.19
Spearman correlation coefficients were used to evaluate potential relations between C-reactive protein levels and lipid levels at study entry and between the change in C-reactive protein levels and the change in lipid values by the end of one year of therapy. The percentage change in C-reactive protein levels that was associated with the use of lovastatin was also computed and compared with the percentage change in C-reactive protein levels among those assigned to the placebo group.
To evaluate the efficacy of lovastatin as compared with placebo in subgroups defined according to base-line levels of lipids and C-reactive protein, we divided the study cohort into four groups of approximately equal size: those with an LDL cholesterol level lower than the median (less than 149.1 mg per deciliter) and a C-reactive protein level lower than the median (less than 0.16 mg per deciliter) (1448 participants); those with an LDL cholesterol level lower than the median and a C-reactive protein level higher than the median (1428 participants); those with an LDL cholesterol level higher than the median and a C-reactive protein level lower than the median (1420 participants); and those with an LDL cholesterol level higher than the median and a C-reactive protein level higher than the median (1446 participants). We then computed the reductions in relative risk associated with lovastatin as compared with placebo in each of these four groups, as well as the number of persons who would have to be treated for five years to prevent one acute coronary event.
To determine whether any observed effects within these groups were sensitive to the choice of lipid variable and to address the fact that the AFCAPS/TexCAPS trial enrolled participants with below-average HDL cholesterol levels, we repeated these analyses using the median base-line ratio of total to HDL cholesterol (5.96) rather than the median base-line LDL cholesterol level.
Results
The overall distribution of C-reactive protein values in this study was similar to that reported in previous studies of primary prevention.8-11 The mean and median levels of C-reactive protein were 0.31 and 0.16 mg per deciliter, respectively, and the ranges of C-reactive protein levels in the four quartiles were less than 0.08 mg per deciliter, 0.08 to less than 0.16 mg per deciliter, 0.16 to 0.35 mg per deciliter, and greater than 0.35 mg per deciliter.
Our data provided minimal evidence of an association between base-line C-reactive protein levels and base-line lipid levels; the Spearman correlation coefficients for the relations between C-reactive protein levels and total, LDL, and HDL cholesterol and triglyceride levels and the ratio of total to HDL cholesterol were 0.069, 0.012, –0.058, 0.129, and 0.092, respectively. Thus, less than 2 percent of the variance in base-line C-reactive protein levels was determined by lipid factors.
Overall, the rates of coronary events increased with the base-line levels of C-reactive protein, so that the relative risks of coronary events in participants assigned to the placebo group as compared with those in the lovastatin group were 1.0, 1.2, 1.3, and 1.7 for the lowest to highest quartile of base-line levels of C-reactive protein (P=0.01). In unadjusted analyses, the risk of acute coronary events increased by 21 percent with each increasing quartile of base-line C-reactive protein levels (95 percent confidence interval, 4 to 41 percent). In similar analyses with control for age, sex, smoking status, hypertension, parental history with respect to coronary disease, and lipid levels, the increase in risk associated with a one-quartile increase in the C-reactive protein level (17 percent; 95 percent confidence interval, 3 to 33 percent) was almost identical in magnitude to that associated with an increase of 1.0 in the ratio of total to HDL cholesterol (18 percent; 95 percent confidence interval, 5 to 33 percent).
Lovastatin therapy was associated with a statistically significant 14.8 percent reduction in the median level of C-reactive protein (95 percent confidence interval, 12.5 to 17.4 percent; P<0.001) at the end of the first year of treatment (Table 1Table 1
Median C-Reactive Protein Levels at Base Line and after One Year of Therapy in the Lovastatin and Placebo Groups.). By contrast, assignment to the placebo group had no effect on the median level of C-reactive protein (median percentage change, 0.0; 95 percent confidence interval, 0.0 to 5.3 percent), although there were more participants with an increase in C-reactive protein levels than with a decrease. Thus, the difference between the lovastatin group and the placebo group in terms of the change in C-reactive protein levels over time was significant (P<0.001). This effect of lovastatin on the level of C-reactive protein was not related to the effect of lovastatin on lipid levels; among the participants in the lovastatin group, the Spearman correlation coefficients for the relation between the percentage change in C-reactive protein level and the percentage change in total, LDL, and HDL cholesterol and triglyceride levels and the ratio of total to HDL cholesterol were –0.001, 0.014, –0.079, –0.013, and 0.061, respectively. Thus, virtually none of the observed variance in the effect of lovastatin on C-reactive protein levels could be explained by lovastatin-induced changes in lipid fractions.Table 2Table 2
Numbers of Acute Coronary Events, Rates of Events, Relative Risks, and Numbers Needed to Treat with Lovastatin to Prevent One Event, According to Base-Line Levels of LDL Cholesterol and C-Reactive Protein. presents the results of efficacy analyses for lovastatin in subgroups of participants delineated according to LDL cholesterol and C-reactive protein levels. As expected, given the overall findings of the trial, lovastatin was clinically effective among participants with LDL cholesterol levels higher than the median, regardless of their C-reactive protein levels (relative risk of acute coronary events, 0.53; 95 percent confidence interval, 0.37 to 0.77; number needed to treat, 42; P=0.001). However, lovastatin was also clinically effective among those with LDL cholesterol levels lower than the median and C-reactive protein levels higher than the median (relative risk, 0.58; 95 percent confidence interval, 0.34 to 0.98; number needed to treat, 48; P=0.04). In contrast, among the participants with LDL cholesterol and C-reactive protein levels that were both lower than the median, the point estimate did not indicate that lovastatin reduced the risk of acute coronary events (relative risk, 1.08; 95 percent confidence interval, 0.56 to 2.08; P=0.74). In these analyses, formal testing for a multiplicative interaction among lovastatin, lipids, and C-reactive protein indicated borderline statistical significance (P=0.06).We evaluated the robustness of these analyses by stratifying the study cohort on the basis of the median base-line ratio of total to HDL cholesterol, rather than on the basis of the base-line LDL cholesterol level, and the results were nearly identical (Table 3Table 3
Numbers of Acute Coronary Events, Rates of Events, Relative Risks, and Numbers Needed to Treat with Lovastatin to Prevent One Event, According to Base-Line Ratio of Total to HDL Cholesterol and C-Reactive Protein Level.). Specifically, lovastatin was highly effective among participants with a base-line ratio of total to HDL cholesterol that was higher than the median (number needed to treat, 47; P=0.005). However, lovastatin was also highly effective among those with a ratio of total to HDL cholesterol lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was far less effective among those with a ratio of total to HDL cholesterol lower than the median who also had a C-reactive protein level lower than the median (number needed to treat, 983; P=0.87) (Table 3).The rates of events among the participants in the placebo group who had lipid levels lower than the median and C-reactive protein levels higher than the median were just as high as the rates of events among those with overt hyperlipidemia (Table 2 and Table 3). Moreover, lovastatin was clinically effective in reducing the risk of acute coronary events among participants with lipid levels lower than the median and C-reactive protein levels higher than the median, but not among those with lipid levels and C-reactive protein levels that were both lower than the median (Figure 1Figure 1
Relative Risks (and 95 Percent Confidence Intervals) Associated with Lovastatin Therapy, According to Base-Line Lipid and C-Reactive Protein Levels.).In these data, the observed efficacy of lovastatin in preventing acute coronary events was not statistically significant among the participants with lipid levels and C-reactive protein levels that were both higher than the median (Figure 1). However, in each of the two subgroups defined according to these criteria, the point estimates of effect indicate an overall net benefit with lovastatin. Furthermore, there was no evidence of any statistically significant difference between the efficacy of lovastatin among the participants with lipid levels and C-reactive protein levels that were both higher than the median and its efficacy among those with lipid levels higher than the median but C-reactive protein levels lower than the median; these data suggest that any small differences between the results in these subgroups probably represent the effects of chance. Finally, because the rates of events were high among participants with lipid levels and C-reactive protein levels that were both higher than the median, the number needed to treat in these subgroups was well below the number considered the threshold for justifying treatment for primary prevention. Indeed, the number needed to treat among participants with lipid levels and C-reactive protein levels that were both higher than the median was of similar magnitude to that found in subgroups in which the efficacy of lovastatin was clearly statistically significant (Table 2 and Table 3).
Discussion
Among the participants in AFCAPS/TexCAPS, base-line C-reactive protein levels were an independent predictor of first acute coronary events. Furthermore, lovastatin appeared to be highly effective in reducing the risk of acute coronary events in participants with elevated C-reactive protein levels but no hyperlipidemia. Indeed, among participants with either an LDL cholesterol level or a ratio of total to HDL cholesterol that was lower than the median but a C-reactive protein level higher than the median, the number needed to treat with lovastatin to prevent one clinical event was virtually identical to that among participants with lipid levels higher than the median. These analyses thus raise the possibility that statin therapy may be clinically effective in persons without hyperlipidemia and suggest that evaluation of the C-reactive protein level may provide a method for the appropriate targeting of statin therapy for primary prevention.20 Finally, lovastatin significantly reduced C-reactive protein levels independently of its effect on lipids.
The results of this study have several implications. First, the current data confirm in a large population of apparently healthy men and women that C-reactive protein can be used to determine the risk of acute coronary events. The effect of the C-reactive protein level on risk was independent of all other factors, including lipid levels, known to predict clinical coronary outcomes. Thus, as in our earlier studies,8,9,16 the current data are consistent with the hypothesis that the addition of an evaluation of the C-reactive protein level to the standard lipid evaluation may provide an improved method of identifying persons at high risk.
Second, in this double-blind trial, the use of lovastatin resulted in a 14.8 percent reduction in median C-reactive protein levels after one year (P<0.001), whereas no change in C-reactive protein levels occurred in participants in the placebo group. Thus, the current data also confirm the findings of the Cholesterol and Recurrent Events (CARE) trial, in which assignment to pravastatin therapy led to a 17.4 percent reduction in median C-reactive protein levels over a five-year period.13 As in the CARE trial, the effect of lovastatin on C-reactive protein levels in our study appeared to be unrelated to any effect of HMG-CoA reductase inhibition on plasma lipid levels. Together, these clinical data provide evidence of nonlipid effects of this class of agents13-15 and suggest that statins may lead to the stabilization of plaque in part through antiinflammatory mechanisms.21-23
Third, although our study is hypothesis-generating, the fact that lovastatin was highly effective among participants without marked hyperlipidemia but with elevated levels of C-reactive protein may have implications for the use of HMG-CoA reductase inhibitors in primary prevention. As outlined in the current guidelines of the National Cholesterol Education Program, strategies to target statin therapy in primary prevention rely largely on LDL cholesterol screening, an approach that results in a reduction in the number needed to treat to prevent one event and improves the cost effectiveness of these agents.5,6 However, as the current data suggest, lovastatin may be highly effective among persons with average and below-average LDL cholesterol levels who have C-reactive protein levels higher than the median. Thus, if the number needed to treat is used to estimate the effect of therapy in primary prevention, then C-reactive protein screening might provide an additional method for targeting the use of statins, particularly when lipid levels are normal or low.
In the current study, the magnitude of the increase in risk associated with higher levels of C-reactive protein is somewhat smaller than that observed in previous studies.8-11 Several aspects of the design of our study probably account for this difference. For example, obese persons and diabetic patients requiring insulin were excluded from the study. Since these groups have elevated C-reactive protein levels and are at increased risk for cardiovascular disease,24 their exclusion would tend to lead to underestimation of the predictive value of the C-reactive protein level. Similarly, because C-reactive protein and lipid levels appear additive in their ability to predict the risk of cardiovascular disease,9,16 the further exclusion from the study of persons with severe hyperlipidemia would also tend to reduce the predictive value of the C-reactive protein level. Finally, nearly 20 percent of the participants in AFCAPS/TexCAPS were taking aspirin, a drug that has also been shown to reduce the effect of C-reactive protein on vascular risk.8 For all of these reasons, estimates of the risk associated with C-reactive protein derived from data from our study cohort would be expected to be lower than those found in unselected populations.20 These issues would not, however, affect the validity of observations made in the context of this study with regard to statin therapy and C-reactive protein, since the participants were assigned to treatment groups in a double-blind manner, without knowledge of C-reactive protein values.
From a clinical perspective, it is important to recognize that half of all heart attacks occur among persons without overt hyperlipidemia7 and thus that novel approaches to the determination of the risk of cardiovascular disease as well as to intervention are needed to improve resource allocation in the primary prevention of myocardial infarction.25 In a recent study of patients with a history of myocardial infarction, randomized use of statin therapy reduced the risk of recurrent coronary events associated with elevated levels of C-reactive protein.26 In the current study of primary prevention, statin therapy was found to reduce the risk of acute coronary events associated with C-reactive protein, even in the absence of hyperlipidemia. Thus, these hypothesis-generating clinical studies, together with the recognition that, biologically, atherosclerosis is in part an inflammatory disease21 and that the lowering of lipid levels may represent an antiinflammatory process,22 appear to provide a rationale for considering wider use of statins than is typically achieved in current practice. Nonetheless, despite large differences in the number needed to treat in this study, the absolute number of events that occurred in each of the four subgroups of participants was small, and formal testing for a multiplicative interaction among lovastatin, lipids, and C-reactive protein indicated borderline statistical significance (P=0.06). Thus, randomized trials of statin therapy among persons without overt hyperlipidemia but with evidence of systemic inflammation are needed in order to test these hypotheses directly.
Supported by grants from the National Heart, Lung, and Blood Institute (HL58755) and the Leducq Foundation, Paris. Dr. Ridker is also the recipient of an Established Investigator Award from the American Heart Association and a Doris Duke Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation. The AFCAPS/TexCAPS trial was supported by grants from Merck.
Dr. Ridker is named as a coinventor on patent applications filed for the use of inflammatory markers in coronary artery disease. Drs. Gotto, Clearfield, Downs, and Weis have either served as consultants to Merck (the manufacturer of lovastatin) or received honorariums from Merck.
We are indebted to Ms. JoAnne Emerson and Mr. Thomas Cook for their assistance with this project.
Source Information
From the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital and Harvard Medical School, Boston (P.M.R., N.R., J.S.M.); the University of North Texas Health Science Center, Fort Worth (M.C., S.E.W.); Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Tex. (J.R.D.); and Weill Medical College of Cornell University, New York (A.M.G.).
Address reprint requests to Dr. Ridker at the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Ave. E., Boston, MA 02215, or at pridker@partners.org.
- References
References
1
Downs JR ,Clearfield M ,Weis S , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-1622
CrossRef | Web of Science | Medline2
Shepherd J ,Cobbe SM ,Ford I , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
Full Text | Web of Science | Medline3
Goldman L ,Weinstein MC ,Goldman PA ,Williams LW . Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-1151
CrossRef | Web of Science | Medline4
Jacobson TA ,Schein JR ,Williamson A ,Ballantyne CM . Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med 1998;158:1977-1989
CrossRef | Web of Science | Medline5
Garber AM . Using cost-effectiveness analysis to target cholesterol reduction. Ann Intern Med 2000;132:833-835
Web of Science | Medline6
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
CrossRef | Web of Science7
Braunwald E . Shattuck Lecture -- cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-1369
Full Text | Web of Science | Medline8
Ridker PM ,Cushman M ,Stampfer MJ ,Tracy RP ,Hennekens CH . Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979[Erratum, N Engl J Med 1997;337:356.]
Full Text | Web of Science | Medline9
Ridker PM ,Hennekens CH ,Buring JE ,Rifai N . C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843
Full Text | Web of Science | Medline10
Koenig W ,Sund M ,Frohlich M , et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242
Web of Science | Medline11
Danesh J ,Whincup P ,Walker M , et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204
CrossRef | Web of Science | Medline12
Ridker PM ,Stampfer MJ ,Rifai N . Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-2485
CrossRef | Web of Science | Medline13
Ridker PM ,Rifai N ,Pfeffer M ,Sacks F ,Braunwald E . Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-235
Web of Science | Medline14
Ridker PM ,Rifai N ,Lowenthal SP . Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-1193
Web of Science | Medline15
Farmer JA . Pleiotropic effects of statins. Curr Atheroscler Rep 2000;2:208-217
CrossRef | Medline16
Ridker PM ,Glynn RJ ,Hennekens CH . C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-2011
Web of Science | Medline17
Downs JR ,Beere PA ,Whitney E , et al. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 1997;80:287-293
CrossRef | Web of Science | Medline18
Rifai N ,Tracy RP ,Ridker PM . Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-2141
Web of Science | Medline19
Gotto AM ,Whitney E ,Stein EA , et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-484
Web of Science | Medline20
Ridker PM . High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818
Web of Science | Medline21
Ross R . Atherosclerosis -- an inflammatory disease. N Engl J Med 1999;340:115-126
Full Text | Web of Science | Medline22
Libby P . Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850
Web of Science | Medline23
Ferro D ,Parrotto S ,Basili S ,Alessandri C ,Violi F . Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-431
CrossRef | Web of Science | Medline24
Visser M ,Bouter LM ,McQuillan GM ,Wener MH ,Harris TB . Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-2135
CrossRef | Web of Science | Medline25
Ridker PM . Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999;130:933-937
Web of Science | Medline26
Ridker PM ,Rifai N ,Pfeffer MA , et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844
Web of Science | Medline
- Citing Articles (474)
Citing Articles
1
Vecih Oduncu, Ayhan Erkol, Mustafa Kurt, İbrahim Halil Tanboğa, Can Yücel Karabay, Cihan Şengül, Mustafa Bulut, Olcay Özveren, Hakan Fotbolcu, Taylan Akgün, Erdem Türkyılmaz, Cevat Kırma. (2012) The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naive patients undergoing primary percutaneous coronary intervention. International Journal of Cardiology
CrossRef2
S Masiha, J Sundström, L Lind. (2012) Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women. Journal of Human Hypertension
CrossRef3
Khurram Nasir, Leslee J. Shaw, Matthew J. Budoff, Paul M. Ridker, Jessica M. Peña. (2012) Coronary Artery Calcium Scanning Should be Used for Primary Prevention. JACC: Cardiovascular Imaging 5:1, 111-118
CrossRef4
Razvan T. Dadu, Vijay Nambi, Christie M. Ballantyne. (2012) Developing and assessing cardiovascular biomarkers. Translational Research
CrossRef5
Kamran I Muhammad, Thomas Morledge, Ravish Sachar, Annette Zeldin, Kathy Wolski, Deepak L Bhatt. (2011) Treatment with ω-3 fatty acids reduces serum C-reactive protein concentration. Clinical Lipidology 6:6, 723-729
CrossRef6
Grant W. Reed, Christopher P. Cannon. (2011) Personalized Therapy Following Drug-Eluting Stenting Using Platelet Function Testing and C-Reactive Protein. Journal of the American College of Cardiology 58:25, 2640-2641
CrossRef7
Scott Kinlay. (2011) Role of C-Reactive Protein When Prescribing a Statin. Current Atherosclerosis Reports
CrossRef8
Mitchell L. Jones, Christopher J. Martoni, Mathieu Parent, Satya Prakash. (2011) Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. British Journal of Nutrition1-9
CrossRef9
N. Verma, V. M. Figueredo. (2011) Statins in non-ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding. International Journal of Clinical Practice 65:11, 1156-1164
CrossRef10
Yasushi Saito. (2011) Pitavastatin: An overview. Atherosclerosis Supplements 12:3, 271-276
CrossRef11
Huseyin Uyarel, Turgay Isik, Erkan Ayhan, Mehmet Ergelen. (2011) Red Cell Distrubition Width (RDW): A novel risk factor for cardiovascular disease. International Journal of Cardiology
CrossRef12
Jerzy Bełtowski, Anna Jamroz-Wiśniewska. (2011) Modulation of H2S metabolism by statins - a new aspect of cardiovascular pharmacology. Antioxidants & Redox Signaling111028091409006
CrossRef13
Paul M Ridker, Tom Thuren, Andrew Zalewski, Peter Libby. (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). American Heart Journal 162:4, 597-605
CrossRef14
Matthias Hermann, Dieter Fischer, Michael M. Hoffmann, Theo Gasser, Kurt Quitzau, Thomas Meinertz, Thomas Münzel, Thomas F. Lüscher. (2011) CRP and CD14 polymorphisms correlate with coronary plaque volume in patients with coronary artery disease – IVUS substudy of the ENCORE trials. Atherosclerosis
CrossRef15
E. Braunwald. (2011) Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. European Heart Journal
CrossRef16
Michael H. Davidson, Christie M. Ballantyne, Terry A. Jacobson, Vera A. Bittner, Lynne T. Braun, Alan S. Brown, W.Virgil Brown, William C. Cromwell, Ronald B. Goldberg, James M. McKenney, Alan T. Remaley, Allan D. Sniderman, Peter P. Toth, Sotirios Tsimikas, Paul E. Ziajka, Kevin C. Maki, Mary R. Dicklin. (2011) Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology 5:5, 338-367
CrossRef17
Markus P. Schneider, Bernhard M. Schmidt, Stefan John, Roland E. Schmieder. (2011) Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. Journal of Hypertension 29:9, 1757-1764
CrossRef18
Ali Zorlu, Gokhan Bektasoglu, Fatma Mutlu Kukul Guven, Omer Tamer Dogan, Esra Gucuk, Meltem Refiker Ege, Hakan Altay, Ziynet Cınar, Izzet Tandogan, Mehmet Birhan Yilmaz. (2011) Usefulness of Admission Red Cell Distribution Width as a Predictor of Early Mortality in Patients With Acute Pulmonary Embolism. The American Journal of Cardiology
CrossRef19
L-S Tam, EK Li, Q Shang, B Tomlinson, VW Lee, KK Lee, M Li, W Pang Kuan, TK Li, L Tseung, GWK Yip, B Freedman, C-M Yu. (2011) Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scandinavian Journal of Rheumatology1-11
CrossRef20
Ralph A. DeFronzo, Muhammad Abdul-Ghani. (2011) Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. The American Journal of Cardiology 108:3, 3B-24B
CrossRef21
Behnood Bikdeli. (2011) C-Reactive Protein, Statins and the Risk of Vascular Events: A Better Understanding. Cardiovascular Drugs and Therapy
CrossRef22
Toshiro Kitagawa, Hideya Yamamoto, Jun Horiguchi, Norihiko Ohashi, Eiji Kunita, Hiroto Utsunomiya, Yasuki Kihara. (2011) Effects of statin therapy on non-calcified coronary plaque assessed by 64-slice computed tomography. International Journal of Cardiology 150:2, 146-150
CrossRef23
Umar Sadat. (2011) Contrast-induced nephropathy: do statins offer protection?. Current Opinion in Cardiology 26:4, 334-337
CrossRef24
Tommaso Gori, Thomas Münzel. (2011) Oxidative stress and endothelial dysfunction: Therapeutic implications. Annals of Medicine 43:4, 259-272
CrossRef25
Vera Krane, Christoph Wanner. (2011) Statins, inflammation and kidney disease. Nature Reviews Nephrology 7:7, 385-397
CrossRef26
Israel F. Charo, Rebecca Taub. (2011) Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nature Reviews Drug Discovery 10:5, 365-376
CrossRef27
Benjamin Rhodes, Barbara G. Fürnrohr, Timothy J. Vyse. (2011) C-reactive protein in rheumatology: biology and genetics. Nature Reviews Rheumatology 7:5, 282-289
CrossRef28
Thura T. Abd, Danny J. Eapen, Ambareesh Bajpai, Abhinav Goyal, Allen Dollar, Laurence Sperling. (2011) The Role of C-Reactive Protein as a Risk Predictor of Coronary Atherosclerosis: Implications from the JUPITER Trial. Current Atherosclerosis Reports 13:2, 154-161
CrossRef29
Yun-Seok Choi, Ho-Joong Youn, Woo-Baek Chung, Hui-Jeong Hwang, Dong-Hyeon Lee, Chul-Soo Park, Jae-Beom Lee, Pum-Joon Kim, Wook-Sung Chung, Man-Young Lee, Kie-Bae Seung, Yong-Ahn Chung. (2011) Uptake of F-18 FDG and ultrasound analysis of carotid plaque. Journal of Nuclear Cardiology 18:2, 267-272
CrossRef30
Harald Loppnow, Li Zhang, Michael Buerke, Michael Lautenschläger, Li Chen, Adrian Frister, Axel Schlitt, Tanja Luther, Nan Song, Britt Hofmann, Stefan Rose-John, Rolf-Edgar Silber, Ursula Müller-Werdan, Karl Werdan. (2011) Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. Journal of Cellular and Molecular Medicine 15:4, 994-1004
CrossRef31
Deepika S. Reddy, Vivian Fonseca. 2011. Screening Patients with Prediabetes and Diabetes for Cardiovascular Disease. , 34-40.
CrossRef32
A. Carr. (2011) Statins as Anti-inflammatory Therapy in HIV Disease?. Journal of Infectious Diseases 203:6, 751-752
CrossRef33
Christiaan L. Meuwese, Peter Stenvinkel, Friedo W. Dekker, Juan J. Carrero. (2011) Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nature Reviews Nephrology 7:3, 166-176
CrossRef34
Niteesh K. Choudhry, Amanda R. Patrick, Robert J. Glynn, Jerry Avorn. (2011) The Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels. Journal of the American College of Cardiology 57:7, 784-791
CrossRef35
Myung-A Kim, Chee Jeong Kim, Jae-Bin Seo, Woo-Yong Chung, Sang-Hyun Kim, Joo-Hee Zo, Eun Yeon Rho, Sue Shin, Jong Hyun Yoon. (2011) The Effect of Aspirin on C-Reactive Protein in Hypertensive Patients. Clinical and Experimental Hypertension 33:1, 47-52
CrossRef36
Fiona Taylor, Kirsten Ward, Theresa HM Moore, Margaret Burke, George Davey Smith, Juan-Pablo Casas, Shah Ebrahim, Fiona Taylor. 2011. Statins for the primary prevention of cardiovascular disease. .
CrossRef37
Sara Lodi, James Carpenter, Peter Egger, Stephen Evans. (2011) Design of cohort studies in chronic diseases using routinely collected databases when a prescription is used as surrogate outcome. BMC Medical Research Methodology 11:1, 36
CrossRef38
Joseph F. Baker, Pauline Walsh, Kevin J. Mulhall. (2011) Statins: A potential role in the management of osteoarthritis?. Joint Bone Spine 78:1, 31-34
CrossRef39
Neil Ruparelia, Janet E Digby, Robin P Choudhury. (2011) Effects of niacin on atherosclerosis and vascular function. Current Opinion in Cardiology 26:1, 66-70
CrossRef40
Sachin Agarwal, J.P. Mohr, Mitchell S.V. Elkind. 2011. Collagen Vascular and Infectious Diseases. , 687-702.
CrossRef41
R. J. Folkeringa, R. G. Tieleman, J. G. Maessen, M. H. Prins, R. Nieuwlaat, H. J. G. M. Crijns. (2010) Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study. Netherlands Heart Journal
CrossRef42
Natalie J. Carter. (2010) Rosuvastatin. American Journal Cardiovascular Drugs 10:6, 383-400
CrossRef43
Paul M. Coen, Michael G. Flynn, Melissa M. Markofski, Brandt D. Pence, Robert E. Hannemann. (2010) Adding exercise to rosuvastatin treatment: influence on C-reactive protein, monocyte toll-like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population. Metabolism 59:12, 1775-1783
CrossRef44
Mario Marzilli. (2010) Pleiotropic Effects of Statins. American Journal Cardiovascular Drugs 10, 3-9
CrossRef45
Luigi Marzio Biasucci, Gina Biasillo, Antonella Stefanelli. (2010) Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clinical Chemistry and Laboratory Medicine 48:12, 1685-1691
CrossRef46
Gregory A Sgueglia, Filippo Crea. (2010) The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?. Journal of Cardiovascular Medicine1
CrossRef47
Paul M. Ridker, Nina P. Paynter, Jacqueline S. Danik, Robert J. Glynn. (2010) Interpretation of Mendelian Randomization Studies and the Search for Causal Pathways in Atherothrombosis: The Need for Caution. Metabolic Syndrome and Related Disorders 8:6, 465-469
CrossRef48
Y.-C. Huang, Y.-J. Lin, J.-S. Chang, S.-Y. Chen, L. Wan, J. J.-C. Sheu, C.-H. Lai, C.-W. Lin, S.-P. Liu, C.-P. Chen, F.-J. Tsai. (2010) Single nucleotide polymorphism rs2229634 in the ITPR3 gene is associated with the risk of developing coronary artery aneurysm in children with Kawasaki disease. International Journal of Immunogenetics 37:6, 439-443
CrossRef49
Paul M. Ridker, Robert J. Glynn. (2010) The JUPITER Trial: Responding to the Critics. The American Journal of Cardiology 106:9, 1351-1356
CrossRef50
Raffaele De Caterina, Marika Massaro, Egeria Scoditti, Maria Annunziata Carluccio. (2010) Pharmacological modulation of vascular inflammation in atherothrombosis. Annals of the New York Academy of Sciences 1207:1, 23-31
CrossRef51
Fumitaka Tanaka, Shinji Makita, Toshiyuki Onoda, Kozo Tanno, Masaki Ohsawa, Kazuyoshi Itai, Kiyomi Sakata, Masayuki Onodera, Yorihiko Koeda, Kazuko Kawarura, Yasuo Terayama, Yuki Yoshida, Akira Ogawa, Akira Okayama, Motoyuki Nakamura. (2010) Prehypertension Subtype With Elevated C-Reactive Protein: Risk of Ischemic Stroke in a General Japanese Population. American Journal of Hypertension 23:10, 1108-1113
CrossRef52
Andrea Corsonello, Sabrina Garasto, Angela Marie Abbatecola, Giuseppina Rose, Giuseppe Passarino, Bruno Mazzei, Luigi Pranno, Enrico Eugenio Guffanti, Silvia Bustacchini, Fabrizia Lattanzio. (2010) Targeting inflammation to slow or delay functional decline: where are we?. Biogerontology 11:5, 603-614
CrossRef53
Duane A. Burnett, Harry R. Davis. 2010. Atherosclerosis I: LDL Cholesterol Lowering. .
CrossRef54
R. J. Bisoendial, S. M. Boekholdt, M. Vergeer, E. S. G. Stroes, J. J. P. Kastelein. (2010) C-reactive protein is a mediator of cardiovascular disease. European Heart Journal 31:17, 2087-2091
CrossRef55
S. A. E. Peters, M. K. Palmer, D. E. Grobbee, J. R. Crouse, D. H. O’Leary, J. S. Raichlen, M. L. Bots. (2010) C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine 268:2, 155-161
CrossRef56
James D. Chalmers, Philip M. Short, Pallavi Mandal, Ahsan R. Akram, Adam T. Hill. (2010) Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respiratory Medicine 104:8, 1081-1091
CrossRef57
John S. Millar, Bonnie Ky, Megan L. Wolfe, Leticia Pruscino, Amanda Baer, Daniel J. Rader. (2010) Short-Term Treatment with High-Dose Atorvastatin Reduces LDL Cholesterol but Shows no Anti-Inflammatory Effects in Normolipidemic Subjects with Normal CRP Levels. Clinical and Translational Science 3:4, 140-146
CrossRef58
Marjolein Geleedst-De Vooght, Anke-Hilse Maitland-van der Zee, Tom Schalekamp, Aukje Mantel-Teeuwisse, Paul Jansen. (2010) Statin Prescribing in the Elderly in the Netherlands. Drugs & Aging 27:7, 589-596
CrossRef59
G.F. Gensini, A.M. Gori, B. Dilaghi, C. Rostagno, A. Gaw, L.M. Blanco-Colio, E. de Teresa, J. Egido, C. Farsang, L.A. Leiter, P. Martineau, A. Nozza, A. Langer. (2010) Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. International Journal of Cardiology 142:3, 257-264
CrossRef60
Gabriel C. Brooks, Michael J. Blaha, Roger S. Blumenthal. (2010) Relation of C-Reactive Protein to Abdominal Adiposity. The American Journal of Cardiology 106:1, 56-61
CrossRef61
A. S. Wierzbicki. (2010) Practice makes perfect: reflections on a primary care treatment-to-target study. International Journal of Clinical Practice 64:8, 1006-1008
CrossRef62
Petter Quist-Paulsen. (2010) Statins and inflammation: an update. Current Opinion in Cardiology 25:4, 399-405
CrossRef63
Basil S. Lewis, David A. Halon. (2010) More Progression Toward Regression?. Journal of the American College of Cardiology 55:24, 2743-2744
CrossRef64
Chan Seok Park, Sang-Hyun Ihm, Ki-Dong Yoo, Dong-Bin Kim, Jong-Min Lee, Hee-Yeol Kim, Wook-Sung Chung, Ki Bae Seung, Jae-Hyung Kim. (2010) Relation Between C-Reactive Protein, Homocysteine Levels, Fibrinogen, and Lipoprotein Levels and Leukocyte and Platelet Counts, and 10-Year Risk for Cardiovascular Disease Among Healthy Adults in the USA. The American Journal of Cardiology 105:9, 1284-1288
CrossRef65
P. Libby, F. Crea. (2010) Clinical implications of inflammation for cardiovascular primary prevention. European Heart Journal 31:7, 777-783
CrossRef66
Ambareesh Bajpai, Abhinav Goyal, Laurence Sperling. (2010) Should We Measure C-reactive Protein on Earth or Just on JUPITER?. Clinical Cardiology 33:4, 190-198
CrossRef67
John G. Raynes. 2010. The Acute Phase Response. .
CrossRef68
Paul M. Ridker, Jean MacFadyen, Michael Cressman, Robert J. Glynn. (2010) Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. Journal of the American College of Cardiology 55:12, 1266-1273
CrossRef69
Michael Clearfield. (2010) New Evidence Extending the Benefit of Treating LDL-C Beyond the Current Guidelines. Current Atherosclerosis Reports 12:1, 1-4
CrossRef70
Hisashi Kai. (2010) Novel non-invasive approach for visualizing inflamed atherosclerotic plaques using fluorodeoxyglucose-positron emission tomography. Geriatrics & Gerontology International 10:1, 1-8
CrossRef71
G. Klose, W. März, T.B. Grammer, S. Nitschmann. (2010) Rosuvastatin zur Primärprävention vaskulärer Komplikationen. Der Internist 51:1, 103-106
CrossRef72
Peter Libby, Yoshihisa Okamoto, Viviane Z. Rocha, Eduardo Folco. (2010) Inflammation in Atherosclerosis:. Circulation Journal 74:2, 213-220
CrossRef73
Tsuyoshi Nozue, Ichiro Michishita, Ichiro Mizuguchi. (2010) Effects of Ezetimibe on Remnant-Like Particle Cholesterol, Lipoprotein (a), and Oxidized Low-Density Lipoprotein in Patients with Dyslipidemia. Journal of Atherosclerosis and Thrombosis 17:1, 37-44
CrossRef74
Parag H. Joshi, Terry A. Jacobson. (2010) Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment. Current Atherosclerosis Reports 12:1, 34-42
CrossRef75
Khaja S Mohammed, Peter R Kowey, Simone Musco. (2010) Adjuvant therapy for atrial fibrillation. Future Cardiology 6:1, 67-81
CrossRef76
Sara Lodi, Stephen J. W. Evans, Peter Egger, James Carpenter. (2010) Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. British Journal of Clinical Pharmacology 69:1, 85-94
CrossRef77
Petra Schnell-Inderst, Ruth Schwarzer, Alexander Göhler, Norma Grandi, Kristin Grabein, Björn Stollenwerk, Jennifer Manne, Volker Klauss, Uwe Siebert, Jürgen Wasem. (2010) Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: A health technology assessment report. International Journal of Technology Assessment in Health Care 26:01, 30
CrossRef78
Young Song, Young Lan Kwak, Yong Seon Choi, Jong Chan Kim, Sang Baek Heo, Jae Kwang Shim. (2010) Effect of preoperative statin therapy on myocardial protection and morbidity endpoints following off-pump coronary bypass surgery in patients with elevated C-reactive protein level. Korean Journal of Anesthesiology 58:2, 136
CrossRef79
Egle Corrado, Manfredi Rizzo, Giuseppe Coppola, Khalil Fattouch, Giuseppina Novo, Ilenia Marturana, Filippo Ferrara, Salvatore Novo. (2010) An Update on the Role of Markers of Inflammation in Atherosclerosis. Journal of Atherosclerosis and Thrombosis 17:1, 1-11
CrossRef80
S Matthijs Boekholdt, John JP Kastelein. (2010) C-reactive protein and cardiovascular risk: more fuel to the fire. The Lancet 375:9709, 95-96
CrossRef81
Eric Y. Yang, Vijay Nambi, Zhengzheng Tang, Salim S. Virani, Eric Boerwinkle, Ron C. Hoogeveen, Brad C. Astor, Thomas H. Mosley, Josef Coresh, Lloyd Chambless, Christie M. Ballantyne. (2009) Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population. Journal of the American College of Cardiology 54:25, 2388-2395
CrossRef82
Vicente Bertomeu Martínez, J. Ramón González-Juanatey. (2009) Markers of Inflammation and Cardiovascular Disease. American Journal Cardiovascular Drugs 9:Supplement 1, 3-7
CrossRef83
Carl J. Lavie, Richard V. Milani, Anil Verma, James H. OʼKeefe. (2009) C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime?. The American Journal of the Medical Sciences 338:6, 486-492
CrossRef84
Peter Libby, Paul M. Ridker, Göran K. Hansson. (2009) Inflammation in Atherosclerosis. Journal of the American College of Cardiology 54:23, 2129-2138
CrossRef85
Mahir Karakas, Wolfgang Koenig. (2009) CRP in Cardiovascular Disease. Herz 34:8, 607-613
CrossRef86
A. S. Wierzbicki. (2009) Hot and bothered: C-reactive protein, inflammation and atherosclerosis. International Journal of Clinical Practice 63:11, 1550-1553
CrossRef87
G. Onder, C. Vedova, F. Landi. (2009) Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia. The Journal of Nutrition, Health and Aging 13:8, 746-756
CrossRef88
B.G. Nordestgaard, J. Zacho. (2009) Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander?. Nutrition, Metabolism and Cardiovascular Diseases 19:8, 521-524
CrossRef89
Mary-Frances O’Connor, Julie E. Bower, Hyong Jin Cho, J. David Creswell, Stoyan Dimitrov, Mary E. Hamby, Michael A. Hoyt, Jennifer L. Martin, Theodore F. Robles, Erica K. Sloan, KaMala S. Thomas, Michael R. Irwin. (2009) To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers. Brain, Behavior, and Immunity 23:7, 887-897
CrossRef90
Peter P. Toth. (2009) Statin therapy, inflammation, and risk for cardiovascular events: The light from JUPITER is illuminating. Current Atherosclerosis Reports 11:5, 323-325
CrossRef91
Francisco AH Fonseca, Maria Cristina O Izar. (2009) Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study. Expert Review of Cardiovascular Therapy 7:9, 1041-1056
CrossRef92
Reza Meshkani, Khosrow Adeli. (2009) Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clinical Biochemistry 42:13-14, 1331-1346
CrossRef93
Chetan V. Hampole, Amit K. Mehrotra, Thenappan Thenappan, Mardi Gomberg-Maitland, Sanjiv J. Shah. (2009) Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension††Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.. The American Journal of Cardiology 104:6, 868-872
CrossRef94
M. Hanefeld. (2009) The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism 11:8, 742-756
CrossRef95
Paul M Ridker, Robert J Glynn. (2009) Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial – Authors' reply. The Lancet 374:9683, 26-27
CrossRef96
PAUL M. RIDKER. (2009) Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). Journal of Thrombosis and Haemostasis 7, 332-339
CrossRef97
Sherifa A. Hamed. (2009) The vascular risk associations with migraine: Relation to migraine susceptibility and progression. Atherosclerosis 205:1, 15-22
CrossRef98
Subodh Verma, Eva M. Lonn, Alykhan Nanji, Kevin Browne, Richard Ward, Annette Robertson, Heather Conradson, Kathy Hildebrand, Rollin Brant, Todd J. Anderson. (2009) Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: The Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results. Canadian Journal of Cardiology 25:7, e236-e240
CrossRef99
Sylvie Perreault, Laura Ellia, Alice Dragomir, Robert Côté, Lucie Blais, Anick Bérard, Lyne Lalonde. (2009) Effect of Statin Adherence on Cerebrovascular Disease in Primary Prevention. The American Journal of Medicine 122:7, 647-655
CrossRef100
Paul M. Ridker. (2009) Moving toward new statin guidelines in a post-JUPITER world: Principles to consider. Current Atherosclerosis Reports 11:4, 249-256
CrossRef101
James K. Liao. (2009) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Current Atherosclerosis Reports 11:4, 243-244
CrossRef102
Tjun Y. Tang, Simon P.S. Howarth, Sam R. Miller, Martin J. Graves, Andrew J. Patterson, Jean-Marie U-King-Im, Zhi Y. Li, Stewart R. Walsh, Andrew P. Brown, Peter J. Kirkpatrick, Elizabeth A. Warburton, Paul D. Hayes, Kevin Varty, Jonathan R. Boyle, Michael E. Gaunt, Andrew Zalewski, Jonathan H. Gillard. (2009) The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Journal of the American College of Cardiology 53:22, 2039-2050
CrossRef103
Viviane Z. Rocha, Peter Libby. (2009) Obesity, inflammation, and atherosclerosis. Nature Reviews Cardiology 6:6, 399-409
CrossRef104
Erdal Cavusoglu. 2009. The Effects of Antiplatelet, Antithrombotic, and Thrombolytic Agents on Inflammation and Circulating Inflammatory Biomarkers. , 67-98.
CrossRef105
René R. S. Packard, Andrew H. Lichtman, Peter Libby. (2009) Innate and adaptive immunity in atherosclerosis. Seminars in Immunopathology 31:1, 5-22
CrossRef106
Jeremiah P Depta, Richard A Krasuski. (2009) Therapy and clinical trials. Current Opinion in Lipidology 20:3, 262-263
CrossRef107
Kubilay Ukinc, Halil Onder Ersoz, Cihangir Erem, Arif Bayram Hacihasanoglu, Suleyman Sami Karti. (2009) Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine 35:3, 380-388
CrossRef108
Barry McDonnell, Stephen Hearty, Paul Leonard, Richard O'Kennedy. (2009) Cardiac biomarkers and the case for point-of-care testing. Clinical Biochemistry 42:7-8, 549-561
CrossRef109
Paul M Ridker, Daniel H. Solomon. (2009) Should patients with rheumatoid arthritis receive statin therapy?. Arthritis & Rheumatism 60:5, 1205-1209
CrossRef110
Claudio Napoli, Francesco Cacciatore. (2009) Novel Pathogenic Insights in the Primary Prevention of Cardiovascular Disease. Progress in Cardiovascular Diseases 51:6, 503-523
CrossRef111
Gianna Fabbri, Aldo Pietro Maggioni. (2009) Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. Advances in Therapy 26:5, 469-487
CrossRef112
Robert Zeiser, Kristina Maas, Sawsan Youssef, Christoph Dürr, Lawrence Steinman, Robert S. Negrin. (2009) Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 127:1, 18-25
CrossRef113
A. S. Wierzbicki. (2009) SEARCHing for JUPITER: starry-eyed optimism is not warranted. International Journal of Clinical Practice 63:5, 685-688
CrossRef114
Ralph AH Stewart. (2009) Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. Future Cardiology 5:3, 231-236
CrossRef115
Paul M Ridker, Eleanor Danielson, Francisco AH Fonseca, Jacques Genest, Antonio M Gotto, John JP Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen, Børge G Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet 373:9670, 1175-1182
CrossRef116
Dean G. Karalis. (2009) Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. Mayo Clinic Proceedings 84:4, 345-352
CrossRef117
D. G. Karalis. (2009) Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. Mayo Clinic Proceedings 84:4, 345-352
CrossRef118
Viviana Noriega, Christian Pennanen, María Pilar Sánchez, Mario Chiong, Marcelo Llancaqueo, Sergio Lavandero, Juan Carlos Prieto. (2009) (TTA)n Polymorphism in 3-Hydroxy-3-Methylglutaryl-Coenzyme A and Response to Atorvastatin in Coronary Artery Disease Patients. Basic & Clinical Pharmacology & Toxicology 104:3, 211-215
CrossRef119
Nathan D. Wong. (2009) Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (the JUPITER trial). Current Cardiovascular Risk Reports 3:2, 83-85
CrossRef120
Nicholas J. Martin, Abby C. Collier, Lance D. Bowen, Karen L. Pritsos, Geoffrey G. Goodrich, Kosta Arger, Gary Cutter, Chris A. Pritsos. (2009) Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 674:1-2, 93-100
CrossRef121
Steven E. Nissen. (2009) The Jupiter trial: Key findings, controversies, and implications. Current Cardiology Reports 11:2, 81-82
CrossRef122
Timm Bauer, Michael Böhm, Ralf Zahn, Claus Jünger, Oliver Koeth, Anselm Gitt, Kurt Bestehorn, Jochen Senges, Uwe Zeymer. (2009) Effect of Chronic Statin Pretreatment on Hospital Outcome in Patients With Acute Non-ST-Elevation Myocardial Infarction. Journal of Cardiovascular Pharmacology 53:2, 132-136
CrossRef123
Ann Samnegård, Johannes Hulthe, Angela Silveira, Carl-Göran Ericsson, Anders Hamsten, Per Eriksson. (2009) Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients. Atherosclerosis 202:2, 550-556
CrossRef124
Meri P. Nantz, Cheryl A. Rowe, Jack F. Bukowski, Susan S. Percival. (2009) Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition 25:2, 147-154
CrossRef125
Brendan M. Everett, Sandeep Bansal, Nader Rifai, Julie E. Buring, Paul M. Ridker. (2009) Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis 202:1, 282-288
CrossRef126
Takashi Motomura, Maki Okamoto, Tetsuhiro Kitamura, Hiroyasu Yamamoto, Michio Otsuki, Nobuyuki Asanuma, Miki Takagi, Shogo Kurebayashi, Kunihiko Hashimoto, Satoru Sumitani, Hiroshi Saito, Haruhiko Kouhara, Kazumasa Nshii, Makoto Nakao, Masafumi Koga, Bunzo Sato, Yasuhiko Morimoto, Soji Kasayama. (2009) Effects of Pitavastatin on Serum Lipids and High Sensitivity C-Reactive Protein in Type 2 Diabetic Patients. Journal of Atherosclerosis and Thrombosis 16:5, 546-552
CrossRef127
A. Vijaya Anand, M. Chandrasekharan, S. Kalavathy, K. Uma, M.P. Saravanan, A. Mohamed Saleem Gani, K. Vijaya Kumar, R. Senthil, P. Sampath Kumar. (2009) The Influencing Aspects of Atorvastatin on C-Reactive Protein and Lipid Profile in Patients with Stroke. International Journal of Biological Chemistry 3:1, 30-34
CrossRef128
Koichiro Tatsumi, Nariyuki Shinozuka, Katsutoshi Nakayama, Nobuyasu Sekiya, Takayuki Kuriyama, Yoshinosuke Fukuchi, . (2009) HOCHUEKKITO IMPROVES SYSTEMIC INFLAMMATION AND NUTRITIONAL STATUS IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Journal of the American Geriatrics Society 57:1, 169-170
CrossRef129
Bengt Fellström, Hallvard Holdaas, Alan G. Jardine, Maria K. Svensson, Mattis Gottlow, Roland E. Schmieder, Faiez Zannad. (2009) Cardiovascular disease in patients with renal disease: the role of statins. Current Medical Research and Opinion 25:1, 271-285
CrossRef130
Jacques Bonnet, R. McPherson, A. Tedgui, D. Simoneau, A. Nozza, P. Martineau, Jean Davignon. (2008) Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clinical Therapeutics 30:12, 2298-2313
CrossRef131
Vera Krane, Karl Winkler, Christiane Drechsler, Jürgen Lilienthal, Winfried März, Christoph Wanner. (2008) Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International 74:11, 1461-1467
CrossRef132
Ridker, Paul M, Danielson, Eleanor, Fonseca, Francisco A.H., Genest, Jacques, Gotto, Antonio M. Jr., Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., MacFadyen, Jean G., Nordestgaard, Børge G., Shepherd, James, Willerson, James T., Glynn, Robert J., . (2008) Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine 359:21, 2195-2207
Full Text133
I. Loftus, M. Thompson. (2008) Plaque Biology: Interesting Science or Pharmacological Treasure Trove?. European Journal of Vascular and Endovascular Surgery 36:5, 507-516
CrossRef134
Kiran Musunuru, Brian G Kral, Roger S Blumenthal, Valentin Fuster, Catherine Y Campbell, Ty J Gluckman, Richard A Lange, Eric J Topol, James T Willerson, Milind Y Desai, Michael H Davidson, Samia Mora. (2008) The use of high-sensitivity assays for C-reactive protein in clinical practice. Nature Clinical Practice Cardiovascular Medicine 5:10, 621-635
CrossRef135
Adriano Paula Sabino, Marinez De Oliveira Sousa, Luciana Moreira Lima, Daniel Dias Ribeiro, Luci Maria Sant'Ana Dusse, Maria Das Graças Carvalho, Ana Paula Fernandes. (2008) ApoB/ApoA-I ratio in young patients with ischemic cerebral stroke or peripheral arterial disease. Translational Research 152:3, 113-118
CrossRef136
Curtis K. Argo, Paola Loria, Stephen H. Caldwell, Amedeo Lonardo. (2008) Statins in liver disease: A molehill, an iceberg, or neither?. Hepatology 48:2, 662-669
CrossRef137
Maho Ikeda, Fuminao Takeshima, Hajime Isomoto, Saburo Shikuwa, Yohei Mizuta, Yoshiyuki Ozono, Shigeru Kohno. (2008) Simvastatin Attenuates Trinitrobenzene Sulfonic Acid-Induced Colitis, but Not Oxazalone-Induced Colitis. Digestive Diseases and Sciences 53:7, 1869-1875
CrossRef138
Yu Asanuma, Annette Oeser, Eran Stanley, David G. Bailey, Ayumi Shintani, C. Michael Stein. (2008) Effects of C-reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin. Archives of Drug Information 1:1, 14-22
CrossRef139
Bobby V. Khan, Sanjay Rajagopalan. (2008) Investigations of Statins in Heart Failure: Inflammatory Biomarkers and Hormones. Heart Failure Clinics 4:2, 171-176
CrossRef140
William E. Boden, Prediman K. Shah, Vipul Gupta, E. Magnus Ohman. (2008) Contemporary Approach to the Diagnosis and Management of Non–ST-Segment Elevation Acute Coronary Syndromes. Progress in Cardiovascular Diseases 50:5, 311-351
CrossRef141
P. Dandona. (2008) Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein. Mayo Clinic Proceedings 83:3, 333-342
CrossRef142
Rainer Hoffmann, Philipp Haager, Hasna Suliman, Philipp Christott, Peter Radke, Rüdiger Blindt, Malte Kelm. (2008) Effect of Statin Therapy Before Q-Wave Myocardial Infarction on Myocardial Perfusion. The American Journal of Cardiology 101:2, 139-143
CrossRef143
Brendan M. Everett, Paul M. Ridker. (2008) Using inflammatory biomarkers to guide lipid therapy. Current Cardiovascular Risk Reports 2:1, 29-34
CrossRef144
Cemil Gürgün, Müge Ildızlı, Oğuz Yavuzgil, Aytül Sin, Anıl Apaydın, Cahide Çınar, Hakan Kültürsay. (2008) The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. International Journal of Cardiology 123:2, 102-107
CrossRef145
Eduard Shantsila, Timothy Watson, Gregory Y.H. Lip. (2008) Statins and inflammation: Reciprocal effectors to endothelial progenitors?. Thrombosis Research 123:1, 1-4
CrossRef146
Hiroyuki Koshiyama, Ataru Taniguchi, Kiyoshi Tanaka, Shinji Kagimoto, Yoshio Fujioka, Kenichi Hirata, Yoshio Nakamura, Akane Iwakura, Kyoko Hara, Taizo Yamamoto, Akira Kuroe, Michihiro Ohya, Shimpei Fujimoto, Yoshiyuki Hamamoto, Sachiko Honjo, Hiroki Ikeda, Koichiro Nabe, Kinsuke Tsuda, Nobuya Inagaki, Yutaka Seino, Noriaki Kume. (2008) Effects of Pitavastatin on Lipid Profiles and High-Sensitivity CRP in Japanese Subjects with Hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) Investigatars. Journal of Atherosclerosis and Thrombosis 15:6, 345-350
CrossRef147
Marie Öhman, Torbjörn Åkerfeldt, Ingela Nilsson, Christer Rosen, Lars-Olof Hansson, Martin Carlsson, Anders Larsson. (2008) Biochemical effects of consumption of eggs containing omega-3 polyunsaturated fatty acids. Upsala Journal of Medical Sciences 113:3, 315-324
CrossRef148
Thomas Quéméneur, Françoise Martin-Nizard, Abdelmejid Kandoussi, Xavier Kyndt, Philippe Vanhille, Eric Hachulla, Pierre-Yves Hatron, Jean-Charles Fruchart, Patrick Duriez, Marc Lambert. (2007) PON1, A New Biomarker of Cardiovascular Disease, Is Low in Patients with Systemic Vasculitis. Seminars in Arthritis and Rheumatism 37:3, 149-155
CrossRef149
Necati Dagli, Mustafa Yavuzkir, Ilgin Karaca. (2007) The Effects of High Dose Pravastatin and Low Dose Pravastatin and Ezetimibe Combination Therapy on Lipid, Glucose Metabolism and Inflammation. Inflammation 30:6, 230-235
CrossRef150
Paul M. Ridker, Francisco A.H. Fonseca, Jacques Genest, Antonio M. Gotto, John J.P. Kastelein, Nardev S. Khurmi, Wolfgang Koenig, Peter Libby, Alberto J. Lorenzatti, Borge G. Nordestgaard, James Shepherd, James T. Willerson, Robert J. Glynn. (2007) Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. The American Journal of Cardiology 100:11, 1659-1664
CrossRef151
Paul M Ridker. (2007) Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity. Nutrition Reviews 65, S253-S259
CrossRef152
JAMES A. LALLY, ERIC M. GNALL, JONATHAN SELTZER, PETER R. KOWEY. (2007) Non-Antiarrhythmic Drugs in Atrial Fibrillation: A Review of Non-Antiarrhythmic Agents in Prevention of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 18:11, 1222-1228
CrossRef153
Kyle A Weant, Aaron M Cook. (2007) Potential Roles for Statins in Critically Ill Patients. Pharmacotherapy 27:9, 1279-1296
CrossRef154
M Fujii, T Inoguchi, Y Maeda, S Sasaki, F Sawada, R Saito, K Kobayashi, H Sumimoto, R Takayanagi. (2007) Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney International 72:4, 473-480
CrossRef155
Jean Ducobu, Marc Claeys, Kathleen Commers, W. Van Mieghem, H. Nachtergaele, M. Vandenbroucke, J. Deforce. (2007) Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study. Current Medical Research and Opinion 23:8, 1821-1827
CrossRef156
Kaisa M. Mäki-Petäjä, Anthony D. Booth, Frances C. Hall, Sharon M.L. Wallace, John Brown, Carmel M. McEniery, Ian B. Wilkinson. (2007) Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis. Journal of the American College of Cardiology 50:9, 852-858
CrossRef157
David Conen, Paul M Ridker. (2007) Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. Biomarkers in Medicine 1:2, 229-241
CrossRef158
Masato Yoneda, Hironori Mawatari, Koji Fujita, Hiroshi Iida, Kyoko Yonemitsu, Shingo Kato, Hirokazu Takahashi, Hiroyuki Kirikoshi, Masahiko Inamori, Yuichi Nozaki, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Tomoyuki Iwasaki, Yasuo Terauchi, Shinji Togo, Shiro Maeyama, Atsushi Nakajima. (2007) High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. Journal of Gastroenterology 42:7, 573-582
CrossRef159
Michael E Farkouh, Sameer Bansilal, Verghese Mathew. (2007) CRP has little incremental value over traditional cardiovascular risk factors in risk stratification. Nature Clinical Practice Cardiovascular Medicine 4:6, 290-291
CrossRef160
Irina Buhaescu, Hassane Izzedine. (2007) Mevalonate pathway: A review of clinical and therapeutical implications. Clinical Biochemistry 40:9-10, 575-584
CrossRef161
Yi-Guan Xu, Sheng-Hua Zhou, Yu-Guang Li, Chun-Hua Zheng, Xu-Ping Li, Qi-Ming Liu, Duan-Min Xu, Shang Chen. (2007) The Mechanism Underlying Vascular Smooth Muscle Cell Apoptosis Induced by Atorvastatin may be Mainly Associated with Down-regulation of Survivin Expression. Cardiovascular Drugs and Therapy 21:3, 145-153
CrossRef162
Grace A McComsey, MaryAnn OʼRiordan, Stanley L Hazen, Dalia El-Bejjani, Shweta Bhatt, Marie-Luise Brennan, Norma Storer, Jerome Adell, Dean A Nakamoto, Vikram Dogra. (2007) Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 21:8, 921-927
CrossRef163
Scott Kinlay. (2007) Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein. Journal of the American College of Cardiology 49:20, 2003-2009
CrossRef164
Paul M. Ridker. (2007) C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk. Journal of the American College of Cardiology 49:21, 2129-2138
CrossRef165
Jing Qian, Baowu Wang, Norma Dawkins, Alexandria Gray, Ralphenia D. Pace. (2007) Reduction of risk factors for cardiovascular diseases in African Americans with a 12-week nutrition education program. Nutrition Research 27:5, 252-257
CrossRef166
M Mahmoudi, N Curzen, P J Gallagher. (2007) Atherogenesis: the role of inflammation and infection. Histopathology 50:5, 535-546
CrossRef167
Juan Tamargo, Ricardo Caballero, Ricardo Gómez, Lucía Núñez, Miguel Vaquero, Eva Delpón. (2007) Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacology & Therapeutics 114:1, 107-126
CrossRef168
Michael J Lipinski, Antonio Abbate, Valentin Fuster, George W Vetrovec. (2007) Drug Insight: statins for nonischemic heart failure—evidence and potential mechanisms. Nature Clinical Practice Cardiovascular Medicine 4:4, 196-205
CrossRef169
Antonio M. Gotto. (2007) Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention. The American Journal of Cardiology 99:5, 718-725
CrossRef170
Jose S. Pulido, Joseph P. McConnell, Lisa M. Peterson, W. Edward Highsmith, Ryan J. Lennon, Sandra C. Bryant, Peter B. Berger, Virend Somers. (2007) Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. Mayo Clinic Proceedings 82:3, 301-307
CrossRef171
J. S. Pulido, J. P. McConnell, L. M. Peterson, W. E. Highsmith, R. J. Lennon, S. C. Bryant, P. B. Berger, V. Somers. (2007) Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. Mayo Clinic Proceedings 82:3, 301-307
CrossRef172
Jason P. Sarkey, Michael P. Richards, Evan B. Stubbs. (2007) Lovastatin attenuates nerve injury in an animal model of Guillain?Barr
syndrome. Journal of Neurochemistry 100:5, 1265-1277
CrossRef173
Natalia Guillén, María A. Navarro, Joaquín C. Surra, Carmen Arnal, Marta Fernández-Juan, Jose Alvaro Cebrián-Pérez, Jesús Osada. (2007) Cloning, characterization, expression and comparative analysis of pig Golgi membrane sphingomyelin synthase 1. Gene 388:1-2, 117-124
CrossRef174
S. Efrati, M. Averbukh, V. Dishy, M. Faygenzo, L. Friedensohn, A. Golik. (2007) The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. European Journal of Clinical Pharmacology 63:2, 113-121
CrossRef175
Sridevi Devaraj, Jason Rogers, Ishwarlal Jialal. (2007) Statins and biomarkers of inflammation. Current Atherosclerosis Reports 9:1, 33-41
CrossRef176
JWG Jacobs, R Geenen. (2007) Het verrassend brede werkingsspectrum van statines. Huisarts en Wetenschap 50:1, 47-49
CrossRef177
Anna Frisinghelli, Antonio Mafrici. (2007) Regression or Reduction in Progression of Atherosclerosis, and Avoidance of Coronary Events, With Lovastatin in Patients With or at High Risk of Cardiovascular Disease. Clinical Drug Investigation 27:9, 591-604
CrossRef178
Feridun Kosar, Yüksel Aksoy, Gulacan Ozguntekin, Ertan Yetkin, Hakan Gunen. (2007) C-Reactive Protein and Aortic Stiffness in Patients with Idiopathic Dilated Cardiomyopathy. Echocardiography 24:1,
CrossRef179
Masaaki Ii, Douglas W. Losordo. (2007) Statins and the endothelium. Vascular Pharmacology 46:1, 1-9
CrossRef180
Sarah D. de Ferranti, Nader Rifai. (2007) C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovascular Pathology 16:1, 14-21
CrossRef181
Saif Anwaruddin, Arman T. Askari, Eric J. Topol. (2007) Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine. Journal of the American College of Cardiology 49:3, 279-289
CrossRef182
Shahirose Jessani, Gregory Y.H. Lip. (2007) Measuring soluble CD40 ligand:interleukin-10 ratio as a prognostic marker in acute myocardial infarction: Yet another prognostic biomarker?. Thrombosis Research 121:3, 289-291
CrossRef183
Kent G. Meredith, Benjamin D. Horne, Robert R. Pearson, Chloe Allen Maycock, Donald L. Lappe, Jeffrey L. Anderson, Joseph B. Muhlestein. (2007) Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin on C-Reactive Protein and Lipoproteins in Patients With Angiographic Evidence of Coronary Arterial Narrowing. The American Journal of Cardiology 99:2, 149-153
CrossRef184
Koichiro Kumagai. (2007) Upstream Therapy for Atrial Fibrillation. Circulation Journal 71:SupplementA, A75-A81
CrossRef185
F. Purroy, J. Montaner, C. A. Molina, P. Delgado, J. F. Arenillas, P. Chacon, M. Quintana, J. Alvarez-Sabin. (2007) C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurologica Scandinavica 115:1, 60-66
CrossRef186
Mary Cushman, Barbara M. Alving. 2007. Risk Factors for Cardiovascular Disease and Arterial Thrombosis. , 371-378.
CrossRef187
F.C. McGillicuddy, I. Lynch, Y.A. Rochev, M. Burke, K.A. Dawson, W.M. Gallagher, A.K. Keenan. (2006) Novel “plum pudding” gels as potential drug-eluting stent coatings: Controlled release of fluvastatin. Journal of Biomedical Materials Research Part A 79A:4, 923-933
CrossRef188
Wolfgang Meyer-Sabellek, Helmut Brasch. (2006) Atherosclerosis, inflammation, leukocyte function and the effect of statins. Journal of Hypertension 24:12, 2349-2351
CrossRef189
Luigina Guasti, Franca Marino, Marco Cosentino, Mariagrazia Cimpanelli, Ramona C Maio, Catherine Klersy, Chiara Crespi, Daniela Restelli, Cinzia Simoni, Ivano Franzetti, Giovanni Gaudio, Patrizio Marnini, Anna M Grandi, Sergio Lecchini, Achille Venco. (2006) Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. Journal of Hypertension 24:12, 2423-2430
CrossRef190
P.-T. Brinkkoetter, U. Gottmann, J. Schulte, F. J. van der Woude, C. Braun, B. A. Yard. (2006) Atorvastatin interferes with activation of human CD4 + T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase-independent apoptosis. Clinical and Experimental Immunology 146:3, 524-532
CrossRef191
Peter Libby, Paul M. Ridker. (2006) Inflammation and Atherothrombosis. Journal of the American College of Cardiology 48:9, A33-A46
CrossRef192
Nobuhiro Tahara, Hisashi Kai, Masatoshi Ishibashi, Hiroyuki Nakaura, Hayato Kaida, Kenkichi Baba, Naofumi Hayabuchi, Tsutomu Imaizumi. (2006) Simvastatin Attenuates Plaque Inflammation. Journal of the American College of Cardiology 48:9, 1825-1831
CrossRef193
James T. Willerson, Paul W Armstrong. 2006. Acute Myocardial Infarction. , 611-646.
CrossRef194
Hans Carl Hasselbalch, Caroline H. Riley. (2006) Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?. Leukemia Research 30:10, 1217-1225
CrossRef195
Josep Maria Manresa, Alberto Zamora, Marta Tom??s, Mariano Sent??, Montserrat Fit??, Mar??a Isabel Covas, Mercedes Alc??ntara, Gl??ria Latorre, Ver??nica Escurriol, Sophie Domingues, Jaume Marrugat. (2006) Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease. European Journal of Cardiovascular Prevention & Rehabilitation 13:5, 738-744
CrossRef196
John A. Farmer. 2006. Inflammatory Mediators and C-Reactive Protein. , 441-462.
CrossRef197
Vera Bittner. 2006. Women and Coronary Heart Disease. , 689-720.
CrossRef198
Michael Clearfield. (2006) Statins and the primary prevention of cardiovascular events. Current Atherosclerosis Reports 8:5, 390-396
CrossRef199
Claudio Rigatto, Patrick Parfrey. (2006) Therapy Insight: management of cardiovascular disease in the renal transplant recipient. Nature Clinical Practice Nephrology 2:9, 514-526
CrossRef200
Matthew A. Roberts, David L. Hare, Sujiva Ratnaike, Francesco L. Ierino. (2006) Cardiovascular Biomarkers in CKD: Pathophysiology and Implications for Clinical Management of Cardiac Disease. American Journal of Kidney Diseases 48:3, 341-360
CrossRef201
David Virsaladze. (2006) Wide Clinical Implementation of Insulin Resistance Syndrome?. Metabolic Syndrome and Related Disorders 4:3, 165-171
CrossRef202
E. Rodilla, J.A. Costa, S. Mares, A. Miralles, C. González, C. Sánchez, J.M. Pascual. (2006) Importancia de los componentes del síndrome metabólico en los valores de proteína C reactiva. Revista Clínica Española 206:8, 363-368
CrossRef203
D Conen, A Zeller, T Dieterle, B Martina. (2006) C-reactive protein and echocardiography have little impact on risk stratification in never-treated hypertensive patients. Journal of Human Hypertension 20:8, 587-592
CrossRef204
Jacques Amar, Laurence Perez, Rémi Burcelin, Bernard Chamontin. (2006) Arteries, inflammation and insulin resistance. Journal of Hypertension 24:Suppl 5, S18-S20
CrossRef205
Anthony S Wierzbicki. (2006) Future approaches to reducing low-density lipoprotein cholesterol. Future Lipidology 1:4, 463-476
CrossRef206
Raed Osman, Philippe L L'Allier, Nader Elgharib, Jean-Claude Tardif. (2006) Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vascular Health and Risk Management 2:3, 221-237
CrossRef207
G. Onder, S. Volpato, R. Liperoti, C. D'Arco, C. Maraldi, R. Fellin, R. Bernabei, F. Landi, . (2006) Total Serum Cholesterol and Recovery From Disability Among Hospitalized Older Adults. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 61:7, 736-742
CrossRef208
A Soto González, D Bellido Guerrero, M Buño Soto, S Pértega Díaz, M Martinez-Olmos, O Vidal. (2006) Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. European Journal of Clinical Nutrition 60:6, 802-809
CrossRef209
Cheng-Lin Hu, Yan-Bo Li, Yan-Hong Tang, Jiang-Bing Chen, Jun Liu, Qi-Zhu Tang, Qing-Hua Zhang, Cong-Xing Huang. (2006) Effects of Withdrawal of Xuezhikang, an Extract of Cholestin, on Lipid Profile and C-reactive Protein: A Short-Term Time Course Study in Patients with Coronary Artery Disease. Cardiovascular Drugs and Therapy 20:3, 185-191
CrossRef210
WH Yin, HL Jen, JW Chen, SJ Lin, MS Young. (2006) Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes & Metabolism 32:3, 229-235
CrossRef211
Jun Yang, Xiang-Ping Li, Shui-Ping Zhao, Jiang Li, Jing-Dong Li, Xiao-Ming Xie. (2006) The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. Clinica Chimica Acta 368:1-2, 183-187
CrossRef212
J.A. Gómez-Gerique. (2006) Utilidad de los marcadores de inflamación en el diagnóstico del riesgo cardiovascular. Clínica e Investigación en Arteriosclerosis 18, 56-71
CrossRef213
Fiona C. McGillicuddy, Daniel O'Toole, Jennifer A. Hickey, William M. Gallagher, Kenneth A. Dawson, Alan K. Keenan. (2006) TGF-β1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascular Pharmacology 44:6, 469-475
CrossRef214
Isabella Sudano, Lukas E. Spieker, Frank Hermann, Andreas Flammer, Roberto Corti, Georg Noll, Thomas F. L??scher. (2006) Protection of Endothelial Function: Targets for Nutritional and Pharmacological Interventions. Journal of Cardiovascular Pharmacology 47:Supplement 2, S136-S150
CrossRef215
Theodore Feldman, Michael Davidson, Arvind Shah, Darbie Maccubbin, Alan Meehan, Michelle Zakson, Diane Tribble, Enrico Veltri, Yale Mitchel. (2006) Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: A post Hoc analysis of subpopulations from three pooled clinical trials. Clinical Therapeutics 28:6, 849-859
CrossRef216
Howard Trachtman, Stephen Futterweit, Christopher Arzberger, Jessica Bod, Judah Goldschmiedt, Haddassah Gorman, Krishna Reddy, Nicholas Franki, Pravin C. Singhal. (2006) Nitric oxide and superoxide in rat mesangial cells: modulation by C-reactive protein. Pediatric Nephrology 21:5, 619-626
CrossRef217
Michael S. Conte. (2006) Invited commentary. Journal of Vascular Surgery 43:5, 977
CrossRef218
Steven J. Weiss, Amy A. Ernst, Todd G. Nick. (2006) Comparison of the National Emergency Department Overcrowding Scale and the Emergency Department Work Index for Quantifying Emergency Department Crowding. Academic Emergency Medicine 13:5, 513-518
CrossRef219
Philip T Rodgers, Dawn C Fuke. (2006) New and Emerging Strategies for Reducing Cardiometabolic Risk Factors. Pharmacotherapy 26:5part2, 13S-31S
CrossRef220
Karen MJ Douglas, Naveed Sattar, George D Kitas. (2006) Potential role of statins and PPARs in rheumatoid arthritis. Future Rheumatology 1:2, 259-274
CrossRef221
Marius Terblanche, Yaniv Almog, Robert S Rosenson, Terry S Smith, Daniel G Hackam. (2006) Statins: panacea for sepsis?. The Lancet Infectious Diseases 6:4, 242-248
CrossRef222
Siu-Ka Mak. (2006) Preventing Cardiovascular Disease in Renal Transplant Recipients. Hong Kong Journal of Nephrology 8:1, 1-4
CrossRef223
Robert C. Green, Sally E. McNagny, Parimala Jayakumar, L. Adrienne Cupples, Kelly Benke, Lindsay A. Farrer. (2006) Statin use and the risk of Alzheimer’s disease: The MIRAGE Study. Alzheimer's and Dementia 2:2, 96-103
CrossRef224
Sotirios Tsimikas, James T. Willerson, Paul M. Ridker. (2006) C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. Journal of the American College of Cardiology 47:8, C19-C31
CrossRef225
Pablo Piñón, Juan Carlos Kaski. (2006) Inflamación, aterosclerosis y riesgo cardiovascular: PAPP-A, Lp-PLA2 y cistatina C. ¿Nuevas aportaciones o información redundante?. Revista Española de Cardiología 59:3, 247-258
CrossRef226
Madhumathi Rao, Bertrand L. Jaber, Vaidyanathapuram S. Balakrishnan. (2006) UNRESOLVED ISSUES IN DIALYSIS: Inflammatory Biomarkers and Cardiovascular Risk: Association or Cause and Effect?. Seminars in Dialysis 19:2, 129-135
CrossRef227
N Horiuchi, T Maeda. (2006) Statins and bone metabolism. Oral Diseases 12:2, 85-101
CrossRef228
Ulrike Resch, Franz Tatzber, Alexandra Budinsky, Helmut Sinzinger. (2006) Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. British Journal of Clinical Pharmacology 61:3, 262-274
CrossRef229
Caren McHenry Martin, Jina Almond. (2006) New Frontiers for Cardiac Risk Assessment: C-Reactive Protein. The Consultant Pharmacist 21:3, 188-206
CrossRef230
Cinzia Sarti, John Gallagher. (2006) The metabolic syndrome. Journal of Diabetes and its Complications 20:2, 121-132
CrossRef231
Andreas Pfützner, Thomas Forst. (2006) High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus. Diabetes Technology & Therapeutics 8:1, 28-36
CrossRef232
C. Y. Huang, T. C. Wu, W. T. Lin, H. B. Leu, C. P. Lin, S. J. Lin, J. W. Chen. (2006) Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. European Journal of Clinical Investigation 36:2, 76-84
CrossRef233
Leonid Yatskar, Edward A. Fisher, Arthur Schwartzbard. (2006) Ezetimibe: Rationale and role in the management of hypercholesterolemia. Clinical Cardiology 29:2, 52-55
CrossRef234
Armin J. Grau, Lars Marquardt, Christoph Lichy. (2006) The effect of infections and vaccinations on stroke risk. Expert Review of Neurotherapeutics 6:2, 175-183
CrossRef235
Steven A. Grover. (2006) PROVE-IT proves that lower is better: A contrary view. Canadian Journal of Cardiology 22, 95B-96B
CrossRef236
Satoru Yamada, Tatsuo Yanagawa, Kazuo Sasamoto, Atsushi Araki, Mariko Miyao, Toshikazu Yamanouchi. (2006) Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Metabolism 55:1, 67-71
CrossRef237
Noriko KOTANI, Keisuke FUKUO, Osamu YASUDA, Ken SUGIMOTO, Tomohiro KATUYA, Yukihiro TAKEMURA, Hidenobu KAWAMOTO, Toyohiko YOKOI, Atsuko SUZUKI, Toshio OGIHARA. (2006) Fas Ligand mRNA Levels of Circulating Leukocytes Reflect Endothelial Dysfunction in Hyperlipidemic but Not in Non-Hyperlipidemic Patients. Hypertension Research 29:4, 217-225
CrossRef238
Michael Clearfield. (2006) Clinical trials report. Current Atherosclerosis Reports 8:1, 7-12
CrossRef239
Young-Oh Shin, Jun-Sang Bae, Jeong-Beom Lee, Jung-Kyu Kim, Young-Joo Kim, Chul Kim, Jae-Ki Ahn, In-Keol Bang, Byoung-Kwon Lee, Timothy Othman, Young-Ki Min, Hun-Mo Yang. (2006) Effect of Cardiac Rehabilitation and Statin Treatment on Anti-HSP Antibody Titers in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention. International Heart Journal 47:5, 671-682
CrossRef240
Nicola Abate, Manisha Chandalia. (2006) Other than potency, are all statins the same?. Current Atherosclerosis Reports 8:1, 26-31
CrossRef241
Paul E. Szmitko, Subodh Verma. (2006) C-Reactive Protein and the Metabolic Syndrome: Useful Addition to the Cardiovascular Risk Profile?. Journal of the CardioMetabolic Syndrome 1:1, 66-69
CrossRef242
Eric P Plaisance, Peter W Grandjean. (2006) Physical Activity and High-Sensitivity C-Reactive Protein. Sports Medicine 36:5, 443-458
CrossRef243
B. K. Zedler, R. Kinser, J. Oey, B. Nelson, H.-J. Roethig, R. A. Walk, P. Kuhl, K. Rustemeier, G. Schepers, K. Von Holt, A. R. Tricker. (2006) Biomarkers of exposure and potential harm in adult smokers of 3–7 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers. Biomarkers 11:3, 201-220
CrossRef244
Lionel H Opie, Patrick J Commerford, Bernard J Gersh. (2006) Controversies in stable coronary artery disease. The Lancet 367:9504, 69-78
CrossRef245
Frank M. van der Sande, Jeroen P. Kooman, Karel M.L. Leunissen. (2006) The Predictive Value of C-Reactive Protein in End-Stage Renal Disease: Is It Clinically Significant?. Blood Purification 24:4, 335-341
CrossRef246
C. J. SONG, A. NAKAGOMI, S. CHANDAR, H. CAI, I. G. S. LIM, H. P. McNEIL, S. B. FREEDMAN, C. L. GECZY. (2006) C-reactive protein contributes to the hypercoagulable state in coronary artery disease. Journal of Thrombosis and Haemostasis 4:1, 98-106
CrossRef247
Elisa Priest, Timothy Church. 2005. Obesity, Cytokines, and Other Inflammatory Markers. , 317-327.
CrossRef248
Mukesh K. Jain, Paul M. Ridker. (2005) Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. Nature Reviews Drug Discovery 4:12, 977-987
CrossRef249
James K Liao. (2005) Clinical implications for statin pleiotropy. Current Opinion in Lipidology 16:6, 624-629
CrossRef250
Gérard Siest, Jean-Brice Marteau, Sandy Maumus, Hind Berrahmoune, Elise Jeannesson, Anastasia Samara, Anne-Marie Batt, Sophie Visvikis-Siest. (2005) Pharmacogenomics and cardiovascular drugs: Need for integrated biological system with phenotypes and proteomic markers. European Journal of Pharmacology 527:1-3, 1-22
CrossRef251
Steven R. Steinhubl, L. Kristin Newby, Marc Sabatine, Shinichiro Uchiyama, Myles Connor, Matthias Endres, Alvaro Avezum, Eric Wahlberg. (2005) Platelets and Atherothrombosis: An Essential Role for Inflammation in Vascular Disease — A Review. International Journal of Angiology 14:4, 211-217
CrossRef252
Pål Aukrust, Arne Yndestad, Torgun Wæhre, Lars Gullestad, Bente Halvorsen, Jan Kristian Damås. (2005) Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Review of Cardiovascular Therapy 3:6, 1111-1124
CrossRef253
Geoffrey S. Ginsburg, Mark P. Donahue, L. Kristin Newby. (2005) Prospects for Personalized Cardiovascular Medicine. Journal of the American College of Cardiology 46:9, 1615-1627
CrossRef254
Paolo Calabr??, Edward T.H Yeh. (2005) The pleiotropic effects of statins. Current Opinion in Cardiology 20:6, 541-546
CrossRef255
Ralph L Sacco, James K Liao. (2005) Drug Insight: statins and stroke. Nature Clinical Practice Cardiovascular Medicine 2:11, 576-584
CrossRef256
Enrique Rodilla, Ana Gómez-Belda, José A. Costa, Miriam Aragó, Amparo Miralles, Carmen González, José M. Pascual. (2005) Variaciones de la proteína C reactiva inducidas por el tratamiento antihipertensivo e hipolipemiante. Medicina Clínica 125:15, 561-564
CrossRef257
Pål Aukrust, Arne Yndestad, Camilla Smith, Wiggo J Sandberg, Thor Ueland, Torgun Wæhre, Bente Halvorsen, Lars Gullestad, Jan Kristian Damås. (2005) Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation. Expert Opinion on Pharmacotherapy 6:13, 2169-2180
CrossRef258
W. Kübler. (2005) Primärprävention der koronaren Herzerkrankung: Was ist in der Praxis bezahlbar?. Zeitschrift für Kardiologie 94:S3, iii92-iii99
CrossRef259
Sonia Waiczies, Timour Prozorovski, Frauke Zipp. (2005) Modulating T cell signaling cascades by HMG-CoA reductase inhibitors. Signal Transduction 5:5, 231-244
CrossRef260
Katherine M. Field. (2005) Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors on High-Sensitivity C-Reactive Protein Levels. Pharmacotherapy 25:10, 1365-1377
CrossRef261
Antonio M. Gotto. (2005) Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. Journal of the American College of Cardiology 46:7, 1219-1224
CrossRef262
M. Flores-Aldana, O. Peralta-Zaragoza, S. Barquera-Cervera. (2005) El paradigma inmune Th1-Th2: un vínculo entre obesidad, aterosclerosis y diabetes mellitus. Clínica e Investigación en Arteriosclerosis 17:5, 232-248
CrossRef263
Matthias Endres. (2005) Statins and stroke. Journal of Cerebral Blood Flow & Metabolism 25:9, 1093-1110
CrossRef264
Stephan J. L. Bakker, Ron T. Gansevoort, Erik M. Stuveling, Rijk O. B. Gans, Dick Zeeuw. (2005) Microalbuminuria and C-reactive protein: Similar messengers of cardiovascular risk?. Current Hypertension Reports 7:5, 379-384
CrossRef265
Valentin Fuster, Pedro R. Moreno, Zahi A. Fayad, Roberto Corti, Juan J. Badimon. (2005) Atherothrombosis and High-Risk Plaque. Journal of the American College of Cardiology 46:6, 937-954
CrossRef266
Edward T. H. Yeh. (2005) High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clinical Cardiology 28:9, 408-412
CrossRef267
Neil L. Coplan, Alexander Chernobelsky. (2005) Global Risk Stratification to Improve Cardiovascular Prevention: Integration of Traditional Risk Factors, Emerging Risk Factors, and New, Noninvasive Cardiovascular Imaging. The American Heart Hospital Journal 3:4, 265-268
CrossRef268
J.C. Laguna. (2005) ¿Actúan las estatinas a través de los PPARα?. Clínica e Investigación en Arteriosclerosis 17, 9-14
CrossRef269
Hirotaka Tsubouchi, Toyoshi Inoguchi, Toshiyo Sonta, Naoichi Sato, Naotaka Sekiguchi, Kunihisa Kobayashi, Hideki Sumimoto, Hideo Utsumi, Hajime Nawata. (2005) Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radical Biology and Medicine 39:4, 444-452
CrossRef270
Amit Khera, Darren K. McGuire, Sabina A. Murphy, Harold G. Stanek, Sandeep R. Das, Wanpen Vongpatanasin, Frank H. Wians, Scott M. Grundy, James A. de Lemos. (2005) Race and Gender Differences in C-Reactive Protein Levels. Journal of the American College of Cardiology 46:3, 464-469
CrossRef271
Antonio Tello, Francisco Marín, Vanessa Roldán, Ana García-Herola, Sofía Lorenzo, Vicente E. Climent, Luis de Teresa, Francisco Sogorb. (2005) Efecto de dosis máximas de atorvastatina en la inflamación, la trombogénesis y la función fibrinolítica en pacientes con cardiopatía isquémica de alto riesgo. Revista Española de Cardiología 58:8, 934-940
CrossRef272
A. Franka Nette, Getu Abraham, Fritz Rupert Ungemach, Reinhard Oertel, Wilhelm Kirch, Kirsten Leineweber, Friedrich-Wilhelm Mohr, Stefan Dhein. (2005) Interaction between simvastatin and metoprolol with respect to cardiac β-adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients. Naunyn-Schmiedeberg's Archives of Pharmacology 372:2, 115-124
CrossRef273
R. Marchioli, G. Levantesi, A. Macchia, A.P. Maggioni, R.M. Marfisi, M.G. Silletta, L. Tavazzi, G. Tognoni, F. Valagussa. (2005) Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial. Journal of Membrane Biology 206:2, 117-128
CrossRef274
MARCELLO TONELLI, FRANK SACKS, MARC PFEFFER, GIAN S JHANGRI, GARY CURHAN. (2005) Biomarkers of inflammation and progression of chronic kidney disease. Kidney International 68:1, 237-245
CrossRef275
Yadon Arad, Louise A. Spadaro, Marguerite Roth, David Newstein, Alan D. Guerci. (2005) Treatment of Asymptomatic Adults With Elevated Coronary Calcium Scores With Atorvastatin, Vitamin C, and Vitamin E. Journal of the American College of Cardiology 46:1, 166-172
CrossRef276
Ankie Amos, L. Kristin Newby. (2005) Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes. Current Cardiology Reports 7:4, 263-269
CrossRef277
María A. Navarro, Rakel Carpintero, Sergio Acín, Jose Miguel Arbonés-Mainar, Lucía Calleja, Ricardo Carnicer, Joaquín C. Surra, Mario A. Guzmán-García, Nieves González-Ramón, María Iturralde, Fermín Lampreave, Andrés Piñeiro, Jesús Osada. (2005) Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine 31:1, 52-63
CrossRef278
Arnold von Eckardstein. (2005) Besteht Bedarf an neuen kardiovaskulären Risikofaktoren? Is there a need for new cardiovascular risk factors?. LaboratoriumsMedizin 29:3, 146-151
CrossRef279
D J A Jenkins, C W C Kendall, A Marchie, D A Faulkner, A R Josse, J M W Wong, R de Souza, A Emam, T L Parker, T J Li, R G Josse, L A Leiter, W Singer, P W Connelly. (2005) Direct comparison of dietary portfolio vs statin on C-reactive protein. European Journal of Clinical Nutrition 59:7, 851-860
CrossRef280
Hsu-Ko Kuo, Chung-Jen Yen, Chia-Hsuin Chang, Chen-Ko Kuo, Jen-Hau Chen, Farzaneh Sorond. (2005) Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. The Lancet Neurology 4:6, 371-380
CrossRef281
Armin J. Grau. (2005) Role of anti-infective strategies in the prevention of stroke. Current Treatment Options in Cardiovascular Medicine 7:3, 187-195
CrossRef282
Paul M. Ridker, David A. Morrow, Lynda M. Rose, Nader Rifai, Christopher P. Cannon, Eugene Braunwald. (2005) Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l. Journal of the American College of Cardiology 45:10, 1644-1648
CrossRef283
Ilyas Atar, Öykü Gülmez, Asli Atar, Hüseyin Bozbas, Aylin Yildirir, Bülent Özin, Mehmet Emin Korkmaz, Haldun Müderrisoglu. (2005) The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention. Clinical Cardiology 28:5, 243-246
CrossRef284
L.M. Blanco-Colio, J. Tuñón, J.L. Martín-Ventura, B. Muñoz-García, J. Egido. (2005) Marcadores biológicos de inflamación y control del tratamiento hipolipemiante. Clínica e Investigación en Arteriosclerosis 17, 25-30
CrossRef285
X. García-Moll, J. Ordóñez-Llanos. (2005) Role of hs-CRP measurements in the current cardiovascular risk assessment. Clinica Chimica Acta 355:1-2, 215-218
CrossRef286
Alok Agrawal. (2005) CRP after 2004. Molecular Immunology 42:8, 927-930
CrossRef287
Masahide Nagano, Motoyuki Nakamura, Kenyu Sato, Fumitaka Tanaka, Toshie Segawa, Katsuhiko Hiramori. (2005) Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population. Atherosclerosis 180:1, 189-195
CrossRef288
M. B
CrossRef289
Paula J. D'Amore. (2005) Evolution of C-Reactive Protein as a Cardiac Risk Factor. Laboratory Medicine 36:4, 234-238
CrossRef290
Philip T. Sager, Rachel Capece, Leslie Lipka, John Strony, Bo Yang, Ramachandran Suresh, Yale Mitchel, Enrico Veltri. (2005) Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179:2, 361-367
CrossRef291
Nenad Trubelja, Carl Vaughan, Neil L. Coplan. (2005) The Role of Statins in Preventing Stroke. Preventive Cardiology 8:2, 98-101
CrossRef292
Schins Annique, Tulner Dorien, Lousberg Richel, Kenis Gunter, Delanghe Joris, J. Crijns Harry, Grauls Gert, Stassen Frank, Maes Michael, Honig Adriaan. (2005) Inflammatory markers in depressed post-myocardial infarction patients. Journal of Psychiatric Research 39:2, 137-144
CrossRef293
Guilherme H. M. Oliveira. (2005) Novel serologic markers of cardiovascular risk. Current Atherosclerosis Reports 7:2, 148-154
CrossRef294
Kimberly A. Dornbrook-Lavender, Melanie S. Joy, Cynthia J. Denu-Ciocca, Hyunsook Chin, Susan L. Hogan, John A. Pieper. (2005) Effects of Atorvastatin on Low-Density Lipoprotein Cholesterol Phenotype and C-Reactive Protein Levels in Patients Undergoing Long-Term Dialysis. Pharmacotherapy 25:3, 335-344
CrossRef295
Claudia Monaco, Anthony Mathur, John F. Martin. (2005) What causes acute coronary syndromes? Applying Koch's postulates. Atherosclerosis 179:1, 1-15
CrossRef296
P. J. Grant. (2005) Inflammatory, atherothrombotic aspects of type 2 diabetes. Current Medical Research and Opinion 21:s1, S5-S12
CrossRef297
E. M. Stuveling. (2005) Biochemical risk markers: a novel area for better prediction of renal risk?. Nephrology Dialysis Transplantation 20:3, 497-508
CrossRef298
James K. Liao, Ulrich Laufs. (2005) PLEIOTROPIC EFFECTS OF STATINS. Annual Review of Pharmacology and Toxicology 45:1, 89-118
CrossRef299
Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene, . (2005) C-Reactive Protein Levels and Outcomes after Statin Therapy. New England Journal of Medicine 352:1, 20-28
Full Text300
Vijay Nambi, Christie M. Ballantyne. (2005) Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. Current Atherosclerosis Reports 7:1, 22-28
CrossRef301
Young Joon Hong, Myung Ho Jeong, Sang Yup Lim, Sang Rok Lee, Kye Hun Kim, Il Suk Sohn, Hyung Wook Park, Ju Han Kim, Weon Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2005) Elevated Preprocedural High-Sensitivity C-Reactive Protein Levels are Associated With Neointimal Hyperplasia and Restenosis Development After Successful Coronary Artery Stenting. Circulation Journal 69:12, 1477-1483
CrossRef302
Paul J. Garcia. (2005) Pleiotropic effects of statins: Moving beyond cholesterol control. Current Atherosclerosis Reports 7:1, 34-39
CrossRef303
Aleksandra Jovelic, Goran Radjen, Stojan Jovelic, Marica Markovic. (2005) Relationship between C-reactive protein and features of the metabolic syndrome in military pilots in the Serbia and Montenegro. Vojnosanitetski pregled 62:11, 811-819
CrossRef304
Shinichi Suzuki. (2005) Induction of TGF-.BETA. and BMP-2 by Simvastatin in Human Periodontal Ligament Cells. Nihon Shishubyo Gakkai Kaishi (Journal of the Japanese Society of Periodontology) 47:3, 168-177
CrossRef305
Béatrice Descamps-Latscha, Véronique Witko-Sarsat, Thao Nguyen-Khoa, Anh Thu Nguyen, Valérie Gausson, Nadya Mothu, Gérard M. London, Paul Jungers. (2005) Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. American Journal of Kidney Diseases 45:1, 39-47
CrossRef306
Rosario Scalia. (2005) Statins and the Response to Myocardial Injury. American Journal of Cardiovascular Drugs 5:3, 163-170
CrossRef307
Bharat Warrier, Rama Mallipeddi, Pradeep Kumar Karla, Chi H. Lee. (2005) The Functional Role of C-Reactive Protein in Aortic Wall Calcification. Cardiology 104:2, 57-64
CrossRef308
Brianna S. Ronnow, Sandra P. Reyna, Joseph B. Muhlestein, Benjamin D. Horne, Chloe A. Allen Maycock, Tami L. Bair, John F. Carlquist, Abdallah G. Kfoury, Jeffrey L. Anderson, Dale G. Renlund. (2005) C-Reactive Protein Predicts Death in Patients with Non-Ischemic Cardiomyopathy. Cardiology 104:4, 196-201
CrossRef309
Subodh Verma, Paul E Szmitko, Paul M Ridker. (2005) C-reactive protein comes of age. Nature Clinical Practice Cardiovascular Medicine 2:1, 29-36
CrossRef310
Jeffrey S. Berns, Ari Mosenkis. (2005) Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis. Hemodialysis International 9:1, 7-22
CrossRef311
Svetlana Ignjatovic. (2005) Determination of high sensitivity C-reactive protein: Clinical and analytical quality. Jugoslovenska medicinska biohemija 24:2, 85-93
CrossRef312
K. M. Kostner. (2004) Activation of the complement system: a crucial link between inflammation and atherosclerosis?. European Journal of Clinical Investigation 34:12, 800-802
CrossRef313
Elia Ascer, Marcelo C. Bertolami, Margareth L. Venturinelli, Valéria Buccheri, Juliana Souza, José C. Nicolau, José Antônio F. Ramires, Carlos V. Serrano. (2004) Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177:1, 161-166
CrossRef314
P. L. MERONI, D. VENTURA. (2004) Statins and autoimmune diseases. APLAR Journal of Rheumatology 7:3, 278-284
CrossRef315
Eduardo Lacson, Nathan W. Levin. (2004) POOR NUTRITIONAL STATUS AND INFLAMMATION: C-Reactive Protein and End-Stage Renal Disease. Seminars in Dialysis 17:6, 438-448
CrossRef316
AJ Marian, Vijay Nambi. (2004) Biomarkers of cardiac disease. Expert Review of Molecular Diagnostics 4:6, 805-820
CrossRef317
Marcello Tonelli, Dorothea Collins, Sander Robins, Hanna Bloomfield, Gary C. Curhan. (2004) Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. American Journal of Kidney Diseases 44:5, 832-839
CrossRef318
Robert S Rosenson. (2004) Statins: can the new generation make an impression?. Expert Opinion on Emerging Drugs 9:2, 269-279
CrossRef319
Gurbir S Bhatia, Michael D Sosin, Derek L Connolly, Russell C Davis. (2004) Statins and rheumatoid arthritis. The Lancet 364:9448, 1853
CrossRef320
Daniel Izquierdo, Nastaran Foyouzi, Jakub Kwintkiewicz, Antoni J. Duleba. (2004) Mevastatin inhibits ovarian theca–interstitial cell proliferation and steroidogenesis. Fertility and Sterility 82, 1193-1197
CrossRef321
Patricia E. Casey. (2004) Markers of Myocardial Injury and Dysfunction. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 15:4, 547-557
CrossRef322
Alexander Geppert, Kurt Huber. (2004) Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. Current Opinion in Critical Care 10:5, 347-353
CrossRef323
G. D. Brinkworth, M. Noakes, B. Parker, P. Foster, P. M. Clifton. (2004) Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with Type 2 diabetes: one-year follow-up of a randomised trial. Diabetologia 47:10, 1677-1686
CrossRef324
Shafie Fazel, Richard D. Weisel, Subodh Verma. (2004) A novel technique to assess flow-mediated vasodilation* *Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 44:7, 1478-1480
CrossRef325
J. K. Liao. (2004) Statins: potent vascular anti-inflammatory agents. International Journal of Clinical Practice 58, 41-48
CrossRef326
K. D. Flemming, R. D. Brown. (2004) Secondary Prevention Strategies in Ischemic Stroke: Identification and Optimal Management of Modifiable Risk Factors. Mayo Clinic Proceedings 79:10, 1330-1340
CrossRef327
Charles Q Meng. (2004) A new era in atherosclerosis drug discovery. Expert Review of Cardiovascular Therapy 2:5, 633-636
CrossRef328
Nader Rifai, G.Russell Warnick. (2004) Quality specifications and the assessment of the biochemical risk of atherosclerosis. Clinica Chimica Acta 346:1, 55-64
CrossRef329
Hironori Nakagami, James K. Liao. (2004) Statins and myocardial hypertrophy. Coronary Artery Disease 15:5, 247-250
CrossRef330
Sandeep Gupta. (2004) Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment?. International Journal of Cardiology 96:2, 131-139
CrossRef331
Dirk H. Walter, Andreas M. Zeiher, Stefanie Dimmeler. (2004) Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coronary Artery Disease 15:5, 235-242
CrossRef332
K. M. Prestwood, C. Unson, M. Kulldorff, M. Cushman. (2004) The Effect of Different Doses of Micronized 17ss-Estradiol on C-Reactive Protein, Interleukin-6, and Lipids in Older Women. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:8, M827-M832
CrossRef333
Marc Evans, Phil McEwan, John R. Peters, Craig J. Currie. (2004) Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate.. Diabetes, Obesity and Metabolism 6:4, 299-307
CrossRef334
Thomas Fehr, Christian Kahlert, Walter Fierz, Helen I Joller-Jemelka, Walter F Riesen, Hans Rickli, Rudolf P Wüthrich, Peter Ammann. (2004) Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 175:1, 83-90
CrossRef335
Martin Busch, Sybille Franke, Andreas Muller, Marco Wolf, Jens Gerth, Undine Ott, Toshimitsu Niwa, Gunter Stein. (2004) Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney International 66:1, 338-347
CrossRef336
Julie P. Sutherland, Benjamin McKinley, Robert H. Eckel. (2004) The Metabolic Syndrome and Inflammation. Metabolic Syndrome and Related Disorders 2:2, 82-104
CrossRef337
Thomas A Abbruzzese, Joaquim Havens, Michael Belkin, Magruder C Donaldson, Anthony D Whittemore, James K Liao, Michael S Conte. (2004) Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. Journal of Vascular Surgery 39:6, 1178-1185
CrossRef338
Ken Ogasawara, Shinichi Mashiba, Youichiro Wada, Makoto Sahara, Kazuo Uchida, Tadanori Aizawa, Tatsuhiko Kodama. (2004) A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis 174:2, 349-356
CrossRef339
Herbert Schuster, Jonathan C Fox. (2004) Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme ™. Expert Opinion on Pharmacotherapy 5:5, 1187-1200
CrossRef340
Charles E. Rackley. (2004) New Clinical Markers Predictive of Cardiovascular Disease. Cardiology in Review 12:3, 151-157
CrossRef341
Danesh, John, Wheeler, Jeremy G., Hirschfield, Gideon M., Eda, Shinichi, Eiriksdottir, Gudny, Rumley, Ann, Lowe, Gordon D.O., Pepys, Mark B., Gudnason, Vilmundur, . (2004) C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. New England Journal of Medicine 350:14, 1387-1397
Full Text342
A. von Eckardstein. (2004) Is there a need for novel cardiovascular risk factors?. Nephrology Dialysis Transplantation 19:4, 761-765
CrossRef343
Ying Zhang, Barbara V. Howard, Linda D. Cowan, Thomas K. Welty, Carl F. Schaefer, Robert A. Wild, Jeunliang Yeh, Elisa T. Lee. (2004) Associations of Postmenopausal Hormone Therapy with Markers of Hemostasis and Inflammation and Lipid Profiles in Diabetic and Nondiabetic American Indian Women: The Strong Heart Study. Journal of Women's Health 13:2, 155-163
CrossRef344
B. Payson Oberg, Elizabeth McMenamin, F. Lee Lucas, Ellen McMonagle, Jason Morrow, T. Alp Ikizler, Jonathan Himmelfarb. (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney International 65:3, 1009-1016
CrossRef345
B. Kasiske, F.G. Cosio, J. Beto, K. Bolton, B.M. Chavers, R. Grimm, A. Levin, B. Masri, R. Parekh, C. Wanner, D.C. Wheeler, P.W.F. Wilson. (2004) Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. American Journal of Transplantation 4:s7, 13-53
CrossRef346
Mehdi H. Shishehbor, Deepak L. Bhatt. (2004) Inflammation and atherosclerosis. Current Atherosclerosis Reports 6:2, 131-139
CrossRef347
Bartlomiej Piechowski-Jozwiak, Julien Bogousslavsky. (2004) Stroke prevention with lipid-lowering therapy. Expert Review of Neurotherapeutics 4:2, 233-239
CrossRef348
Anna Savo, Pierangela Maria Maiorano, Graziano Onder, Roberto Bernabei. (2004) Pharmacoepidemiology and disability in older adults: can medications slow the age-related decline in physical function?. Expert Opinion on Pharmacotherapy 5:2, 407-413
CrossRef349
Tabassome Simon, Pierre Boutouyrie, Anne Gompel, Sophie Christin-Maitre, Stephane Laurent, Christian Thuillez, Faiez Zannad, Corine Bernaud, Patrice Jaillon, . (2004) Rationale, design and methods of the CASHMERE study+. Fundamental and Clinical Pharmacology 18:1, 131-138
CrossRef350
M. Macini, J. Stamler. (2004) Diet for preventing cardiovascular diseases. Nutrition, Metabolism and Cardiovascular Diseases 14:1, 52-57
CrossRef351
Jason T. Call, Efthymios N. Deliargyris, L Kristin Newby. (2004) Focusing on Inflammation in the Treatment of Atherosclerosis. Cardiology in Review 12:4, 194-200
CrossRef352
Luis Miguel Blanco-Colio, Julio I Osende, Jose Luis Mart??n-Ventura, Jos?? Tu????n, Jes??s Egido. (2004) Statins in Hypertensive Patients. Drugs 64:Supplement 2, 61-67
CrossRef353
W. l. Stone, G. Krishnaswamy, H. Yang. 2004. The role of fat-soluble nutrients and antioxidants in preventing heart disease. , 56-76.
CrossRef354
Antonie JHHM van Oostrom, Jeroen PH van Wijk, Manuel Castro Cabezas. (2004) Lipaemia, Inflammation and Atherosclerosis. Drugs 64:Supplement 2, 19-41
CrossRef355
Stefan James. (2004) Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin. Upsala Journal of Medical Sciences 109:2, 71-122
CrossRef356
Atsushi HOZAWA, Kaori OHMORI, Shinichi KURIYAMA, Taichi SHIMAZU, Kaijun NIU, Aya WATANDO, Satoru EBIHARA, Toshifumi MATSUI, Masataka ICHIKI, Ryoichi NAGATOMI, Hidetada SASAKI, Ichiro TSUJI. (2004) C-Reactive Protein and Peripheral Artery Disease among Japanese Elderly: the Tsurugaya Project. Hypertension Research 27:12, 955-961
CrossRef357
Andras Vermes, Istvan Vermes. (2004) Genetic Polymorphisms in Cytochrome P450 Enzymes. American Journal of Cardiovascular Drugs 4:4, 247-255
CrossRef358
Shigeru Morikawa, Wakako Takabe, Chikage Mataki, Yoichiro Wada, Akashi Izumi, Yasushi Saito, Takao Hamakubo, Tatsuhiko Kodama. (2004) Global Analysis of RNA Expression Profile in Human Vascular Cells Treated with Statins. Journal of Atherosclerosis and Thrombosis 11:2, 62-72
CrossRef359
Motoyuki NAKAMURA, Toshiyuki ONODA, Kazuyoshi ITAI, Masaki OHSAWA, Kenyu SATOU, Toshiaki SAKAI, Toshie SEGAWA, Junko SASAKI, Yoko TONARI, Katsuhiko HIRAMORI, Akira OKAYAMA. (2004) Association between Serum C-reactive Protein Levels and Microalbuminuria: A Population-Based Cross-Sectional Study in Northern Iwate, Japan. Internal Medicine 43:10, 919-925
CrossRef360
Guy De Backer, Ettore Ambrosioni, Knut Broch-Johnsen, Carlos Brotons, Renata Cifkova, Jean Dallongeville, Shah Ebrahim, Ole Faergeman, Ian Graham, Guiseppe Mancia, Volkert Manger Cats, Kristina Orth-Gom??r, Joep Perk, Kalevi Py??r??l??, Jos?? L. Rodicio, Susana Sans, Vedat Sansoy, Udo Sechtem, Sigmund Silber, Troels Thomsen, David Wood. (2003) European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation 10:Supplement 1, S1-S78
CrossRef361
Neil J. Stone. (2003) Are Statins Indicated for the Primary Prevention of Coronary Heart Disease in Octogenarians? Protagonist Viewpoint. The American Journal of Geriatric Cardiology 12:6, 351-354
CrossRef362
Hani Jneid, Deepak L Bhatt. (2003) Advances in antiplatelet therapy. Expert Opinion on Emerging Drugs 8:2, 349-363
CrossRef363
Robert S Rosenson. (2003) Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Review of Cardiovascular Therapy 1:4, 495-505
CrossRef364
Harold Bays, Evan A Stein. (2003) Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opinion on Pharmacotherapy 4:11, 1901-1938
CrossRef365
Jos?? L. Torres, Paul M. Ridker. (2003) Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Current Opinion in Cardiology 18:6, 471-478
CrossRef366
G.M. Hirschfield. (2003) C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 96:11, 793-807
CrossRef367
Russell P. Tracy. 2003. Atherogenesis and Coronary Heart Disease. .
CrossRef368
Tzung-Dau Wang, Wen-Jone Chen, Jong-Wei Lin, Ching-Chih Cheng, Ming-Fong Chen, Yuan-Teh Lee. (2003) Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170:2, 315-323
CrossRef369
Gavin J. Blake. (2003) Inflammatory biomarkers of the patient with myocardial insufficiency. Current Opinion in Critical Care 9:5, 369-374
CrossRef370
Marcello Rattazzi, Massimo Puato, Elisabetta Faggin, Barbara Bertipaglia, Alberto Zambon, Paolo Pauletto. (2003) C-reactive protein and interleukin-6 in vascular disease. Journal of Hypertension 21:10, 1787-1803
CrossRef371
David W. Lehman. (2003) Novel Serum Cardiac Risk Biomarkers: Risk Assessment for Primary Prevention. Primary Care Case Reviews 6:3, 121-128
CrossRef372
Ulrich Laufs, James K. Liao. (2003) Isoprenoid metabolism and the pleiotropic effects of statins. Current Atherosclerosis Reports 5:5, 372-378
CrossRef373
Gérald Luc, Dominique Arveiler, Alun Evans, Philippe Amouyel, Jean Ferrieres, Jean-Marie Bard, Latifa Elkhalil, Jean-Charles Fruchart, Pierre Ducimetiere. (2003) Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: The PRIME Study. Atherosclerosis 170:1, 169-176
CrossRef374
Paul M. Ridker, Shari S. Bassuk, Peter P. Toth. (2003) C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. Current Atherosclerosis Reports 5:5, 341-349
CrossRef375
Kazunari Matsumoto, Yasunori Sera, Yasuyo Abe, Yukitaka Ueki, Tan Tominaga, Seibei Miyake. (2003) Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. Atherosclerosis 169:2, 317-321
CrossRef376
Shunichi Kojima, Mikio Shida, Hiroyuki Yokoyama. (2003) Changes in C-reactive Protein Plasma Levels During Low-density Lipoprotein Apheresis. Therapeutic Apheresis and Dialysis 7:4, 431-434
CrossRef377
Gregorio Brevetti, Antonio Silvestro, Simonetta Di Giacomo, Roxana Bucur, AnnaMaria Di Donato, Vittorio Schiano, Francesco Scopacasa. (2003) Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. Journal of Vascular Surgery 38:2, 374-379
CrossRef378
Thomas P Erlinger, Michelle E Tarver-Carr, Neil R Powe, Lawrence J Appel, Josef Coresh, Mark S Eberhardt, Frederick L Brancati. (2003) Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. American Journal of Kidney Diseases 42:2, 256-263
CrossRef379
Anders Larsson, Lars-Olof Hansson. (2003) Evaluation of a modified hsCRP method for point-of-service testing. Clinica Chimica Acta 334:1-2, 249-252
CrossRef380
Ibrahim E. Fahdi, Venkat Gaddam, Luis Garza, Francesco Romeo, Jawahar L. Mehta. (2003) Inflammation, infection, and atherosclerosis. Brain, Behavior, and Immunity 17:4, 238-244
CrossRef381
Michael Clearfield. (2003) Evolution of Cholesterol Management Therapies: Exploiting Potential for Further Improvement. American Journal of Therapeutics 10:4, 275-281
CrossRef382
P. H. Winocour, M. Fisher. (2003) Prediction of cardiovascular risk in people with diabetes. Diabetic Medicine 20:7, 515-527
CrossRef383
Peter K Henke, Pasu Sukheepod, Mary C Proctor, Gilbert R Upchurch, James C Stanley. (2003) Clinical relevance of peripheral vascular occlusive disease in patients with rheumatoid arthritis and systemic lupus erythematosus 11Competition of interest: none.. Journal of Vascular Surgery 38:1, 111-115
CrossRef384
José L. Torres, Paul M. Ridker. (2003) High Sensitivity C-Reactive Protein in Clinical Practice. The American Heart Hospital Journal 1:3, 207-211
CrossRef385
Yoshihiro Fukumoto, Hiroyuki Tsutsui, Miyuki Tsuchihashi, Akihiro Masumoto, Akira Takeshita. (2003) The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. Journal of the American College of Cardiology 42:2, 211-216
CrossRef386
SVATI H. SHAH, L. KRISTIN NEWBY. (2003) C-Reactive Protein: A Novel Marker of Cardiovascular Risk. Cardiology in Review 11:4, 169-179
CrossRef387
Neil MacDonald, Alexandra M Easson, Vera C Mazurak, Geoffrey P Dunn, Vickie E Baracos. (2003) Understanding and managing cancer cachexia. Journal of the American College of Surgeons 197:1, 143-161
CrossRef388
Mark B. Pepys, Gideon M. Hirschfield. (2003) C-reactive protein: a critical update. Journal of Clinical Investigation 111:12, 1805-1812
CrossRef389
Carmine Zoccali, Francesca Mallamaci, Giovanni Tripepi. (2003) Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney International 63:s85, 105-110
CrossRef390
W. Koenig. (2003) C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. Nephrology Dialysis Transplantation 18:6, 1039-1041
CrossRef391
Matthias Girndt, Christof Ulrich, Harald Kaul, Urban Sester, Martina Sester, Hans Kohler. (2003) Uremia-associated immune defect: The IL-10-CRP axis. Kidney International 63:s84, 76-79
CrossRef392
Wolfgang Koenig. (2003) Update on C-reactive protein as a risk marker in cardiovascular disease. Kidney International 63:s84, 58-61
CrossRef393
Markus Ketteler, Christoph Wanner, Thomas Metzger, Philipp Bongartz, Ralf Westenfeld, Ulrich Gladziwa, Leon J. Schurgers, Cees Vermeer, Willi Jahnen-Dechent, Jurgen Floege. (2003) Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. Kidney International 63:s84, 84-87
CrossRef394
Antonio M. Gotto. (2003) Risks and benefits of continued aggressive statin therapy. Clinical Cardiology 26:S3, 3-12
CrossRef395
(2003) REFERENCES. American Journal of Kidney Diseases 41, S77-S91
CrossRef396
Paul M. Ridker. (2003) Connecting the role of C-reactive protein and statins in cardiovascular disease. Clinical Cardiology 26:S3, 39-44
CrossRef397
Edward T. H. Yeh, Robert P. Palusinski. (2003) C-reactive protein: The pawn has been promoted to queen. Current Atherosclerosis Reports 5:2, 101-105
CrossRef398
Dale R. Shepard, Hani Jneid, Holly L. Thacker. (2003) Gender, hyperlipidemia, and coronary artery disease. Comprehensive Therapy 29:1, 7-17
CrossRef399
Claudio Rigatto. (2003) THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiac Disease in Renal Transplant Recipients. Seminars in Dialysis 16:2, 106-110
CrossRef400
Luca Mascitelli, Francesca Pezzetta. (2003) The PROSPER trial. The Lancet 361:9355, 427
CrossRef401
Erik M Stuveling, Hans L Hillege, Stephan JL Bakker, Reinold OB Gans, Paul E de Jong, Dick de Zeeuw. (2003) C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney International 63:2, 654-661
CrossRef402
Joseph G. Feldman, Philip Goldwasser, Susan Holman, Jack DeHovitz, Howard Minkoff. (2003) C-Reactive Protein Is an Independent Predictor of Mortality in Women With HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 32:2, 210-214
CrossRef403
Dianna Magliano, Danny Liew, Emma Ashton, Vijaya Sundararajan, John McNeil. (2003) Journal of Cardiovascular Risk 10:1, 41-55
CrossRef404
James Shepherd, Gerard J Blauw, Michael B Murphy. (2003) The PROSPER trial. The Lancet 361:9355, 428
CrossRef405
M. J. Kendall, S. L. Nuttall. (2003) Coronary artery disease - more disease, more patients, better treatment. Journal of Clinical Pharmacy and Therapeutics 28:1, 1-4
CrossRef406
Robert Cramb. (2003) Therapy and clinical trials. Current Opinion in Lipidology 14:1, 111-113
CrossRef407
Gavin J Blake, Paul M Ridker. (2003) C-reactive protein and other inflammatory risk markers in acute coronary syndromes. Journal of the American College of Cardiology 41:4, S37-S42
CrossRef408
Stavroula Tsiara, Moses Elisaf, Dimitri P. Mikhailidis. (2003) Early vascular benefits of statin therapy. Current Medical Research and Opinion 19:6, 540-556
CrossRef409
Luis Miguel Blanco-Colio, José Tuñón, Jose Luis Martín-Ventura, Jesús Egido. (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney International 63:1, 12-23
CrossRef410
Moira M.B. Mungall, Allan Gaw, James Shepherd. (2003) Statin Therapy in the Elderly. Drugs & Aging 20:4, 263-275
CrossRef411
Enzo Ragucci, Joel Zonszein, William H. Frishman. (2003) Pharmacotherapy of Diabetes Mellitus: Implications for the Prevention and Treatment of Cardiovascular Disease. Heart Disease 5:1, 18-33
CrossRef412
Peter Libby, Masanori Aikawa. (2003) Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clinical Cardiology 26:S1, 11-14
CrossRef413
Peter H. Jones. (2003) Comparing HMG-CoA reductase inhibitors. Clinical Cardiology 26:S1, 15-20
CrossRef414
Benjamin J. Ansell, Karol E. Watson, Robert E. Weiss, Gregg C. Fonarow. (2003) hsCRP and HDL Effects of Statins Trial (CHEST): Rapid Effect of Statin Therapy on C-Reactive Protein and High-Density Lipoprotein Levels. Heart Disease 5:1, 2-7
CrossRef415
Joshua M. Spin, Randall H. Vagelos. (2003) Early use of statins in acute coronary syndromes. Current Atherosclerosis Reports 5:1, 44-51
CrossRef416
Rivka Rotstein, Tali Landau, Abraham Twig, Ardon Rubinstein, Michael Koffler, Daniel Justo, Doron Constantiner, David Zeltser, Itzhak Shapira, Tamar Mardi, Yelena Goldin, Shlomo Berliner. (2002) The erythrocyte adhesiveness/aggregation test (EAAT). Atherosclerosis 165:2, 343-351
CrossRef417
Sanne van Wissen, Mieke D Trip, Tineke J Smilde, Jacqueline de Graaf, Anton F.H Stalenhoef, John J.P Kastelein. (2002) Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 165:2, 361-366
CrossRef418
Mosca, Lori, . (2002) C-Reactive Protein — To Screen or Not to Screen?. New England Journal of Medicine 347:20, 1615-1617
Full Text419
Ridker, Paul M., Rifai, Nader, Rose, Lynda, Buring, Julie E., Cook, Nancy R., . (2002) Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. New England Journal of Medicine 347:20, 1557-1565
Full Text420
Sander J Robins, Jean-Pierre Despres. (2002) MRC/BHF Heart Protection Study. The Lancet 360:9347, 1780
CrossRef421
Carlos A Labarrere, Joshua B Lee, David R Nelson, Mohammed Al-Hassani, Steven J Miller, Douglas E Pitts. (2002) C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. The Lancet 360:9344, 1462-1467
CrossRef422
Gabriele Weitz-Schmidt. (2002) Statins as anti-inflammatory agents. Trends in Pharmacological Sciences 23:10, 482-487
CrossRef423
A. G. Olsson, G. G. Schwartz, L. Jonasson, C. Linderfalk. (2002) Are early clinical effects of cholesterol lowering mediated through effects on inflammation?. Acta Physiologica Scandinavica 176:2, 147-150
CrossRef424
Shlomo Berliner, David Zeltser, Itzhak Shapira, Einor Assayag, Tamar Mardi, Jacob Serov, Stanislav Aharonov, Nadir Arber, Rivka Rotstein. (2002) Journal of Cardiovascular Risk 9:5, 281-286
CrossRef425
Filippo Crea, Cmlaudia Monaco, Gaetano A. Lanza, Elena Maggi, Francesca Ginnetti, Domenico Cianflone, Giampaolo Niccoli, Thomas Cook, Giorgio Bellomo, John Kjekshus. (2002) Inflammatory predictors of mortality in the scandinavian simvastatin survival study. Clinical Cardiology 25:10, 461-466
CrossRef426
Antonio M. Gotto. (2002) Statins and C-Reactive Protein: Considering a Novel Marker of Cardiovascular Risk. Preventive Cardiology 5:4, 200-203
CrossRef427
R. S. Wright, J. G. Murphy, K. A. Bybee, S. L. Kopecky, J.-M. LaBlanche. (2002) Statin Lipid-Lowering Therapy for Acute Myocardial Infarction and Unstable Angina: Efficacy and Mechanism of Benefit. Mayo Clinic Proceedings 77:10, 1085-1092
CrossRef428
James S. Zebrack, Jeffrey L. Anderson. (2002) Role of Inflammation in Cardiovascular Disease: How to Use C-Reactive Protein in Clinical Practice. Progress in Cardiovascular Nursing 17:4, 174-185
CrossRef429
C Kluft, M.P.M de Maat. (2002) Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low levels of C-reactive protein. Vascular Pharmacology 39:3, 99-104
CrossRef430
Nader Rifai, Paul M Ridker. (2002) Inflammatory markers and coronary heart disease. Current Opinion in Lipidology 13:4, 383-389
CrossRef431
James K. Liao. (2002) Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation 110:3, 285-288
CrossRef432
Aloys Berg, Daniel König, Martin Halle, Manfred Baumstark. (2002) Physical exercise in dyslipoproteinemias: An update. European Journal of Sport Science 2:4, 1-13
CrossRef433
Robert S. Rosenson, Wolfgang Koenig. (2002) High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. Current Opinion in Cardiology 17:4, 325-331
CrossRef434
Patrick L. McGeer, Edith G. McGeer, Koji Yasojima. (2002) Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. Experimental Gerontology 37:7, 925-929
CrossRef435
Rachael Wyman, Mark Vitcenda, Patrick McBride. (2002) The Surveillance of Cholesterol Management in the Cardiac Rehabilitation Setting. Journal of Cardiopulmonary Rehabilitation 22:4, 245-250
CrossRef436
WILLIAM H. FRISHMAN, ANJUM ISMAIL. (2002) Role of Infection in Atherosclerosis and Coronary Artery Disease: A New Therapeutic Target?. Cardiology in Review 10:4, 199-210
CrossRef437
Mariusz L. Kielar, D. Rohan Jeyarajah, Christopher Y. Lu. (2002) The regulation of ischemic acute renal failure by extrarenal organs. Current Opinion in Nephrology and Hypertension 11:4, 451-457
CrossRef438
Joshua M. Spin, Randall H. Vagelos. (2002) Early use of statins in acute coronary syndromes. Current Cardiology Reports 4:4, 289-297
CrossRef439
Monte Malach, Pascal James Imperato. (2002) The Importance of Lipid Evaluation and Management in the Prevention and Treatment of Acute Myocardial Infarction. Preventive Cardiology 5:3, 131-137
CrossRef440
Gavin J Blake, Paul M Ridker, Karen M Kuntz. (2002) Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels. Journal of the American College of Cardiology 40:1, 49-55
CrossRef441
David A Brown, Samuel N Breit, Julie Buring, W Douglas Fairlie, Asne R Bauskin, Tao Liu, Paul M Ridker. (2002) Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. The Lancet 359:9324, 2159-2163
CrossRef442
Eberhard Ritz, Ralf Dikow, Marcin Adamzcak, Martin Zeier. (2002) Congestive Heart Failure Due to Systolic Dysfunction: The Cinderella of Cardiovascular Management in Dialysis Patients. Seminars in Dialysis 15:3, 135-140
CrossRef443
Ralf Dikow, Marcin Adamczak, Daniel Ernesto Henriquez, Eberhard Ritz. (2002) Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney International 61:s80, 5-10
CrossRef444
Michael B Clearfield. (2002) Statins: balancing benefits, efficacy and safety. Expert Opinion on Pharmacotherapy 3:5, 469-477
CrossRef445
Josef Veselka, Šárka Procházková, Radka Duchoňová, Ingrid Bolomová, Tatʼána Urbanová, David Tesař, Tomáš Honěk. (2002) Relationship of C-reactive protein to presence and severity of coronary atherosclerosis in patients with stable angina pectoris or a pathological exercise test. Coronary Artery Disease 13:3, 151-154
CrossRef446
Lewis Wexler. (2002) Ethical Considerations in Image-Based Screening for Coronary Artery Disease. Topics in Magnetic Resonance Imaging 13:2, 95-106
CrossRef447
Ralf Dikow, Martin Zeier, Eberhard Ritz. (2002) DIALYZING THE ELDERLY: ISSUES AND CONCERNS: Cardiovascular Abnormalities and Hypertension in the Elderly Dialysis Patient. Seminars in Dialysis 15:2, 121-126
CrossRef448
G HILLIS. (2002) Management of Stable Angina and Unstable Angina/Non-ST-elevation Myocardial Infarction. Medicine 30:4, 64-70
CrossRef449
John A. Farmer, Guillermo Torre-Amione. (2002) Atherosclerosis and inflammation. Current Atherosclerosis Reports 4:2, 92-98
CrossRef450
Luther T. Clark. (2002) Vascular inflammation as a therapeutic target for prevention of cardiovascular disease. Current Atherosclerosis Reports 4:2, 77-81
CrossRef451
Sarah de Ferranti, Nader Rifai. (2002) C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clinica Chimica Acta 317:1-2, 1-15
CrossRef452
James S Zebrack, Joseph B Muhlestein, Benjamin D Horne, Jeffrey L Anderson. (2002) C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. Journal of the American College of Cardiology 39:4, 632-637
CrossRef453
Julia Platts. (2002) Therapy and clinical trials. Current Opinion in Lipidology 13:1, 109-111
CrossRef454
Ralf Dikow, Vedat Schwenger, Martin Zeier, Eberhard Ritz. (2002) Do AV Fistulas Contribute to Cardiac Mortality in Hemodialysis Patients?. Seminars in Dialysis 15:1, 14-17
CrossRef455
Fahmy W.F. Hanna, Basil G. Issa. (2002) Hyperlipidaemia and cardiovascular disease: C-reactive protein and atherosclerosis - new dimensions. Current Opinion in Lipidology 13:1, 101-103
CrossRef456
Ashwani Bedi, Gregory C. Flaker. (2002) How Do HMG-CoA Reductase Inhibitors Prevent Stroke?. American Journal of Cardiovascular Drugs 2:1, 7-14
CrossRef457
Roberto Wayhs, Allan Zelinger, Paolo Raggi. (2002) High coronary artery calcium scores pose an extremely elevated risk for hard events. Journal of the American College of Cardiology 39:2, 225-230
CrossRef458
Gilbert R. Thompson, Christopher J. Packard, Neil J. Stone. (2002) Goals of statin therapy: Three viewpoints. Current Atherosclerosis Reports 4:1, 26-33
CrossRef459
Mohammed H. Moghadasian. (2002) Statins and Menopause. Drugs 62:17, 2421-2431
CrossRef460
Christopher C. Case, Christie M. Ballantyne. (2002) Statins and inflammatory markers. Current Atherosclerosis Reports 4:1, 42-47
CrossRef461
Edmund A. Bermudez, Paul M. Ridker. (2002) C-Reactive Protein, Statins, and the Primary Prevention of Atherosclerotic Cardiovascular Disease. Preventive Cardiology 5:1, 42-46
CrossRef462
Tom Sanders. (2001) Nutrition and therapeutics. Current Opinion in Lipidology 12:6, 659-661
CrossRef463
James Shepherd. (2001) Issues surrounding age: vascular disease in the elderly. Current Opinion in Lipidology 12:6, 601-609
CrossRef464
Olivier Meyer. (2001) Atherosclerosis and connective tissue diseases. Joint Bone Spine 68:6, 564-575
CrossRef465
Frenette, Paul S., . (2001) Locking a Leukocyte Integrin with Statins. New England Journal of Medicine 345:19, 1419-1421
Full Text466
David C Crossman. (2001) Opportunities for the treatment of inflammation in cardiovascular disease. Expert Opinion on Pharmacotherapy 2:11, 1751-1763
CrossRef467
Serge Masson, Aldo Pietro Maggioni, Pietro Ghezzi, Riccardo Bertini, Roberto Latini, Laura Calvillo. (2001) Cardiac protection by pharmacological modulation of inflammation. Expert Opinion on Investigational Drugs 10:11, 1913-1924
CrossRef468
Christian W Hamm, Michel Bertrand, Eugene Braunwald. (2001) Acute coronary syndrome without ST elevation: implementation of new guidelines. The Lancet 358:9292, 1533-1538
CrossRef469
(2001) The Antiinflammatory Effects of Statins. New England Journal of Medicine 345:16, 1209-1211
Full Text470
Niall Sheehy, Carl J Vaughan, Norman Delanty. (2001) Statins and neuroprotection. Expert Opinion on Investigational Drugs 10:10, 1847-1853
CrossRef471
Sheila A Doggrell. (2001) Statins in the 21st century: end of the simple story?. Expert Opinion on Investigational Drugs 10:9, 1755-1766
CrossRef472
Robert C. Kaplan, William H. Frishman. (2001) Systemic Inflammation as a Cardiovascular Disease Risk Factor and as a Potential Target for Drug Therapy. Heart Disease326-332
CrossRef473
&NA;. (2001) Statins: can CRP levels determine coronary risk?. Inpharma Weekly &NA;:1295, 12
CrossRef474
Munford, Robert S., . (2001) Statins and the Acute-Phase Response. New England Journal of Medicine 344:26, 2016-2018
Full Text
